US5776944A - 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof - Google Patents
7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof Download PDFInfo
- Publication number
- US5776944A US5776944A US08/825,992 US82599297A US5776944A US 5776944 A US5776944 A US 5776944A US 82599297 A US82599297 A US 82599297A US 5776944 A US5776944 A US 5776944A
- Authority
- US
- United States
- Prior art keywords
- dmso
- sub
- compound
- carboxylic acid
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- 238000000034 method Methods 0.000 title claims description 43
- 230000008569 process Effects 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title description 84
- -1 quinolone compound Chemical class 0.000 claims abstract description 58
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 42
- 150000001875 compounds Chemical class 0.000 claims description 199
- 238000006243 chemical reaction Methods 0.000 claims description 65
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 44
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 150000007529 inorganic bases Chemical group 0.000 claims description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 2
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- ZRCVYEYHRGVLOC-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-methoxyimino-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(CN)C(=NOC)CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-UHFFFAOYSA-N 0.000 abstract 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 abstract 1
- 101150035983 str1 gene Proteins 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 41
- 238000003786 synthesis reaction Methods 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- 238000012360 testing method Methods 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 28
- 229910052739 hydrogen Inorganic materials 0.000 description 27
- 241000588724 Escherichia coli Species 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 25
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 241000191967 Staphylococcus aureus Species 0.000 description 21
- 239000001257 hydrogen Substances 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 150000008064 anhydrides Chemical class 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 12
- 239000007858 starting material Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 12
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 11
- 229960003405 ciprofloxacin Drugs 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- 241000588697 Enterobacter cloacae Species 0.000 description 10
- 241000588915 Klebsiella aerogenes Species 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 229910052731 fluorine Inorganic materials 0.000 description 10
- 150000002431 hydrogen Chemical group 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- 239000012265 solid product Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 9
- JIYMVSQRGZEYAX-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1C(CN)C(=NOC)CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 JIYMVSQRGZEYAX-UHFFFAOYSA-N 0.000 description 8
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 150000007660 quinolones Chemical class 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 7
- 229940035423 ethyl ether Drugs 0.000 description 7
- 230000036571 hydration Effects 0.000 description 7
- 238000006703 hydration reaction Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- NCQJVUJTSUTFLG-UHFFFAOYSA-N (4-methoxyiminopyrrolidin-3-yl)methanamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CON=C1CNCC1CN NCQJVUJTSUTFLG-UHFFFAOYSA-N 0.000 description 6
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 6
- 241000191940 Staphylococcus Species 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 229940098779 methanesulfonic acid Drugs 0.000 description 6
- 229960001699 ofloxacin Drugs 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- CGXLVFZJJOXEDF-UHFFFAOYSA-N 1,8-naphthyridine-3-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CN=C21 CGXLVFZJJOXEDF-UHFFFAOYSA-N 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 241000588917 Citrobacter koseri Species 0.000 description 5
- 241000194032 Enterococcus faecalis Species 0.000 description 5
- 241000191938 Micrococcus luteus Species 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 4
- 101000740462 Escherichia coli Beta-lactamase TEM Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- 125000003544 oxime group Chemical group 0.000 description 4
- 150000002923 oximes Chemical class 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- NMASXYCNDJMMFR-UHFFFAOYSA-N 1-cyclopropyl-6,7,8-trifluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C12=C(F)C(F)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 NMASXYCNDJMMFR-UHFFFAOYSA-N 0.000 description 3
- KNEXGVPHPGXAGF-UHFFFAOYSA-N 1-cyclopropyl-6,7-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C12=CC(F)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 KNEXGVPHPGXAGF-UHFFFAOYSA-N 0.000 description 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
- CQPUZLMNORVQPG-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6,7,8-trifluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)C=2C(N)=C(F)C(F)=C(F)C=2N1C1CC1 CQPUZLMNORVQPG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000589291 Acinetobacter Species 0.000 description 3
- 102100024439 Adhesion G protein-coupled receptor A2 Human genes 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101000833358 Homo sapiens Adhesion G protein-coupled receptor A2 Proteins 0.000 description 3
- 101001096065 Homo sapiens Plexin domain-containing protein 1 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102100037891 Plexin domain-containing protein 1 Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000006504 o-cyanobenzyl group Chemical group [H]C1=C([H])C(C#N)=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- WQJZXSSAMGZVTM-UHFFFAOYSA-N 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(F)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 WQJZXSSAMGZVTM-UHFFFAOYSA-N 0.000 description 2
- FKKUVCHFRDLBHN-UHFFFAOYSA-N 1-ethyl-6,7,8-trifluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(F)C(F)=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 FKKUVCHFRDLBHN-UHFFFAOYSA-N 0.000 description 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000006491 4-t-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ZHFGWIOLVRSZNQ-UHFFFAOYSA-N 8-chloro-1-cyclopropyl-6,7-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C12=C(Cl)C(F)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 ZHFGWIOLVRSZNQ-UHFFFAOYSA-N 0.000 description 2
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 241000588767 Proteus vulgaris Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- TYFYIOQYACPZQK-UHFFFAOYSA-N [4-[(2-methylpropan-2-yl)oxyimino]pyrrolidin-1-ium-3-yl]methylazanium;dichloride Chemical compound Cl.Cl.CC(C)(C)ON=C1CNCC1CN TYFYIOQYACPZQK-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- OTJZCIYGRUNXTP-UHFFFAOYSA-N but-3-yn-1-ol Chemical compound OCCC#C OTJZCIYGRUNXTP-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- QHVFOYQMSXYDOS-UHFFFAOYSA-N n-but-3-ynylhydroxylamine Chemical compound ONCCC#C QHVFOYQMSXYDOS-UHFFFAOYSA-N 0.000 description 2
- GNCJFWWZVGYNBX-UHFFFAOYSA-N n-pyrrolidin-1-ylhydroxylamine Chemical group ONN1CCCC1 GNCJFWWZVGYNBX-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229940007042 proteus vulgaris Drugs 0.000 description 2
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 2
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 description 2
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical compound N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 229940072132 quinolone antibacterials Drugs 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 238000005979 thermal decomposition reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- WNWJRFNGBZMBAJ-MWLCHTKSSA-N (3s,4r)-4-methyl-1-(1,8-naphthyridin-2-yl)pyrrolidin-3-amine Chemical class C1[C@@H](N)[C@H](C)CN1C1=CC=C(C=CC=N2)C2=N1 WNWJRFNGBZMBAJ-MWLCHTKSSA-N 0.000 description 1
- YZBFISOEIGOFAF-UHFFFAOYSA-N (4-methoxyiminopyrrolidin-3-yl)methanamine Chemical compound CON=C1CNCC1CN YZBFISOEIGOFAF-UHFFFAOYSA-N 0.000 description 1
- KXZBNJFMRWYHIG-UHFFFAOYSA-N (4-phenylmethoxyiminopyrrolidin-3-yl)methanamine Chemical compound NCC1CNCC1=NOCC1=CC=CC=C1 KXZBNJFMRWYHIG-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DTYLXDLAOLOTKT-UHFFFAOYSA-N 1,4-dihydroquinoline-3-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)=CNC2=C1 DTYLXDLAOLOTKT-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- BZHLKSGCIWAFDU-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-6,7-difluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound C12=NC(F)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1F BZHLKSGCIWAFDU-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 1
- HKZGKLFYUWKTPG-UHFFFAOYSA-N 3-n-methoxypyrrolidine-3,4-diamine Chemical compound CONC1CNCC1N HKZGKLFYUWKTPG-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CQDQACBVUQQHCK-UHFFFAOYSA-N 4-(aminomethyl)pyrrolidin-3-one Chemical compound NCC1CNCC1=O CQDQACBVUQQHCK-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- GZQKFRIFSJKMBU-UHFFFAOYSA-N 4-oxopyrrolidine-3-carbonitrile Chemical compound O=C1CNCC1C#N GZQKFRIFSJKMBU-UHFFFAOYSA-N 0.000 description 1
- RQOFJKZLDJQRJL-UHFFFAOYSA-N 5-amino-7-[3-(aminomethyl)-4-[(2-methylpropan-2-yl)oxyimino]pyrrolidin-1-yl]-1-cyclopropyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(CN)C(=NOC(C)(C)C)CN1C1=CC(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1 RQOFJKZLDJQRJL-UHFFFAOYSA-N 0.000 description 1
- UFVJPAKVHAXUFE-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-[(2-methylpropan-2-yl)oxyimino]pyrrolidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(CN)C(=NOC(C)(C)C)CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F UFVJPAKVHAXUFE-UHFFFAOYSA-N 0.000 description 1
- QTFKCKODOQIGJP-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-[(2-methylpropan-2-yl)oxyimino]pyrrolidin-1-yl]-1-cyclopropyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(CN)C(=NOC(C)(C)C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F QTFKCKODOQIGJP-UHFFFAOYSA-N 0.000 description 1
- UHSGHSLJMPINEA-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-[(2-methylpropan-2-yl)oxyimino]pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(CN)C(=NOC(C)(C)C)CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 UHSGHSLJMPINEA-UHFFFAOYSA-N 0.000 description 1
- GRZJMJXJUOAKBI-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-[(2-methylpropan-2-yl)oxyimino]pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(CN)C(=NOC(C)(C)C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 GRZJMJXJUOAKBI-UHFFFAOYSA-N 0.000 description 1
- MTGKIZNUPRJSOK-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-[(2-methylpropan-2-yl)oxyimino]pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC(CN)C(=NOC(C)(C)C)C1 MTGKIZNUPRJSOK-UHFFFAOYSA-N 0.000 description 1
- WGHQHYSRULCQTK-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-[(2-methylpropan-2-yl)oxyimino]pyrrolidin-1-yl]-1-ethyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CC(CN)C(=NOC(C)(C)C)C1 WGHQHYSRULCQTK-UHFFFAOYSA-N 0.000 description 1
- XTKKAGFAWWPTQL-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-phenylmethoxyiminopyrrolidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound NCC1CN(C=2C(=CC=3C(=O)C(C(O)=O)=CN(C=3N=2)C=2C(=CC(F)=CC=2)F)F)CC1=NOCC1=CC=CC=C1 XTKKAGFAWWPTQL-UHFFFAOYSA-N 0.000 description 1
- LRNNKSYRIPNAHL-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-phenylmethoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound NCC1CN(C=2C(=CC=3C(=O)C(C(O)=O)=CN(C=3N=2)C2CC2)F)CC1=NOCC1=CC=CC=C1 LRNNKSYRIPNAHL-UHFFFAOYSA-N 0.000 description 1
- GIECHVBHQIPGDE-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-phenylmethoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N(C1)CC(CN)C1=NOCC1=CC=CC=C1 GIECHVBHQIPGDE-UHFFFAOYSA-N 0.000 description 1
- IRIFPRDXZKZADF-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-phenylmethoxyiminopyrrolidin-1-yl]-1-ethyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N(C1)CC(CN)C1=NOCC1=CC=CC=C1 IRIFPRDXZKZADF-UHFFFAOYSA-N 0.000 description 1
- WTCJJEJMYYASNT-UHFFFAOYSA-N 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound C12=NC(Cl)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1F WTCJJEJMYYASNT-UHFFFAOYSA-N 0.000 description 1
- OXNZWNNMJBOZQO-UHFFFAOYSA-N 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound C12=NC(Cl)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 OXNZWNNMJBOZQO-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101100177155 Arabidopsis thaliana HAC1 gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100096890 Caenorhabditis elegans str-217 gene Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021581 Cobalt(III) chloride Inorganic materials 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 101100434170 Oryza sativa subsp. japonica ACR2.1 gene Proteins 0.000 description 1
- 101100434171 Oryza sativa subsp. japonica ACR2.2 gene Proteins 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 101150108015 STR6 gene Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- QVCGXRQVUIKNGS-UHFFFAOYSA-L cobalt(2+);dichloride;hydrate Chemical compound O.Cl[Co]Cl QVCGXRQVUIKNGS-UHFFFAOYSA-L 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000001916 cyano esters Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- SBPUJTNHAUBDKF-UHFFFAOYSA-N ethyl 2-(2-cyanoethylamino)acetate Chemical compound CCOC(=O)CNCCC#N SBPUJTNHAUBDKF-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002221 gravimetric sorption analysis Methods 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- DLWAIQHBNNLIPC-UHFFFAOYSA-N n-methoxypyrrolidin-3-amine Chemical compound CONC1CCNC1 DLWAIQHBNNLIPC-UHFFFAOYSA-N 0.000 description 1
- UFACNXSRCYXIKN-UHFFFAOYSA-N n-pyrrolidin-3-ylhydroxylamine Chemical compound ONC1CCNC1 UFACNXSRCYXIKN-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 150000005054 naphthyridines Chemical class 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- NUXCOKIYARRTDC-UHFFFAOYSA-N o-ethylhydroxylamine;hydron;chloride Chemical compound Cl.CCON NUXCOKIYARRTDC-UHFFFAOYSA-N 0.000 description 1
- DBTXKJJSFWZJNS-UHFFFAOYSA-N o-phenylhydroxylamine;hydrochloride Chemical compound Cl.NOC1=CC=CC=C1 DBTXKJJSFWZJNS-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960000321 oxolinic acid Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960001732 pipemidic acid Drugs 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- NGXSWUFDCSEIOO-UHFFFAOYSA-N pyrrolidin-3-amine Chemical group NC1CCNC1 NGXSWUFDCSEIOO-UHFFFAOYSA-N 0.000 description 1
- OQCUGPQOZNYIMV-UHFFFAOYSA-N pyrrolidin-3-ylmethanamine Chemical group NCC1CCNC1 OQCUGPQOZNYIMV-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical group 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960003889 rosoxacin Drugs 0.000 description 1
- XBPZXDSZHPDXQU-UHFFFAOYSA-N rosoxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=C1C1=CC=NC=C1 XBPZXDSZHPDXQU-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 238000007514 turning Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to a novel quinoline(naphthyridine) carboxylic acid derivative having an excellent antibacterial activity. More specifically, the present invention relates to a novel quinoline(naphthyridine)carboxylic acid derivative represented by the following formula (I), which has an 4-aminomethyl-3-oximepyrrolidine substituent on 7-position of the quinolone nucleus and shows a superior antibacterial activity in contrast to the known quinolone antibacterial agents and also has a broad antibacterial spectrum and a highly improved pharmacokinetic property: ##STR2## and its pharmaceutically acceptable non-toxic salt, its physiologically hydrolyzable ester, solvate and isomer, in which
- R represents hydrogen, methyl or amino
- Q represents C--H, C--F, C--Cl, C--OH, C--CH 3 , C--O--CH 3 or N;
- R 1 represents cyclopropyl, ethyl, or phenyl which is substituted with one or more fluorine atom(s);
- R 2 represents one of the following a) through e):
- R 3 and R 4 independently of one another represent hydrogen or C 1 -C 3 alkyl or R 3 and R 4 together with a nitrogen atom to which they are attached can form a ring.
- the present invention also relates to a process for preparing the compound of formula (I), as defined above, and an antibacterial composition comprising the compound of formula (I) as an active component.
- nalidixic acid was first introduced as an agent for treating urinary tract infection (see, G. Y. Lesher, et al., J. Med. Chem. 5, 1063-1065 (1962)), numerous quinoline carboxylic acid antibacterial agents, including oxolinic acid, rosoxacin, pipemidic acid, etc., have been developed. However, these early-stage antibaterial agents have a little activity against gram-positive bacterial strains and thus have been used only against gram-negative strains.
- norfloxacin which is the quinolone compound having a fluorine on 6-position has been newly developed (see, H. Koga, et al., J. Med. Chem., 23, 1358-1363 (1980)), and thereafter an extensive study to develop various quinolone antibacterial compounds has been conducted.
- norfloxacin since norfloxacin has a weak antibacterial activity against gram-positive strains and shows poor distribution and absorption in living body, it has been used only for treatment of diseases including urinary tract infections, gastro-intestinal infections, sexually transmitted diseases and the like. Thereafter, ciprofloxacin (see, R. Wise, et al., J. Antimicrob.
- the compounds in use or under clinical test include mainly the derivatives having a piperazine substituent on 7-position of the quinolone nucleus as in ciprofloxacin or ofloxacin.
- a compound having an 3-amino or 3-aminomethylpyrrolidine group introduced into 7-position has an increased activity against gram-positive strains, in comparison with the compounds having 7-piperazine group, while maintaining a potent activity against gram-negative strains.
- the compounds having pyrrolidine substituent have a low solubility in water in comparison with the compounds having piperazine substituent, and thus their in-vivo antibacterial activity is not so high as the in-vitro activity. Accordingly, numerous study has been continuously conducted to improve the disadvantage of the compounds having pyrrolidine substituent, that is, to increase the solubility in water and to improve the pharmacokinetic property.
- R' represents hydrogen or methyl
- X represents C--H, C--F or N
- n denotes 1 or 2.
- the compound A! has some disadvantages that it shows a good antibacterial activity against gram-positive strains but a relatively weak activity against gram-negative strains, and also has a relatively low antibacterial activity in in-vivo test.
- Japanese Laid-open Patent Publication No. (Hei) 01-100165 (1989) discloses the compound having the following general formula B!: ##STR8## in which R represents cyclopropyl, 2,4-difluorophenyl or 4-hydroxy-phenyl;
- X represents C--H, C--F or C--Cl
- R' represents oxime or hydroxyaminopyrrolidine-derived substituent.
- European Early Patent Publication No. 0 541 086 discloses the quinolone compound having the following general formula C!: ##STR10## in which R and R 1 independently of one another represent hydrogen or C 1 -C 5 alkyl;
- R 2 represents hydrogen, amino, fluoro or hydroxy
- R 3 represents C 3 -C 7 cycloalkyl
- R 4 represents methoxy or fluoro
- R 5 and R 6 can be identical with or different from each other and independently of one another represent hydrogen or alkyl, or
- R 5 and R 6 together can form C 3 -C 5 cycloalkyl
- n denotes 0 or 1
- n denotes an integer of 1 to 3.
- the compound of formula C! does not include any compound having both oxime group and aminomethyl group on 7-position, and therefore, is different from the compound of the present invention.
- the common characteristic feature of the known oxime or hydroxyamine-derived compounds as mentioned above is that they exhibit a good activity against gram-positive strains including MRSA (Methicillin Resistant Staphylococcus aureus) strains in comparison with the early developed quinolone compounds but show a weak activity against gram-negative strains in comparison with the antibacterial agents including ofloxacin or ciprofloxacin. Therefore, it can be said that their antibacterial spectrum may be narrower than that of the known ofloxacin or ciprofloxacin antibacterial compound.
- MRSA Metal Resistant Staphylococcus aureus
- the present inventors have extensively studied to develop the novel oxime-aminomethyl compound, which shows a potent antibacterial activity against broad spectrum pathogenic strains including resistant strains and also exhibits more improved pharmacokinetic properties and high absorption in living body, by introducing various substituted pyrrolidine groups into 7-position of quinoline nucleus and determining pharmacological activities of the resulting compounds.
- the quinolone compounds having the general formula (I), as defined above, wherein 4-aminomethyl-3-(optionally substituted)oxime-pyrrolidine group is introduced into 7-position of quinoline nucleus can satisfy such purpose, and thus completed the present invention.
- It is a further object of the present invention to provide an antibacterial composition comprising the novel quinoline (naphthyridine)carboxylic acid derivative of formula (I) as an active component.
- FIG. 1 represents the moisture adsorption velocity profile of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate at 25° C.;
- FIG. 2 represents the isothermal moisture adsorption profile of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate at 25° C.;
- FIG. 3 represents the equilibrium moisture content of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate ⁇ 3 hydrate at a relative humidity of 23 to 75%;
- FIG. 4 represents test result on moisture adsorption of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate ⁇ 1.5 hydrate;
- FIG. 5 represents the powder X-ray diffraction pattern of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate anhydride;
- FIG. 6 represents the powder X-ray diffraction pattern of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate ⁇ 3 hydrate;
- FIG. 7 represents the powder X-ray diffraction pattern of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate ⁇ 1.5 hydrate;
- FIG. 8 represents the variation in moisture content with elapsed time of 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclocropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate anhydride taken after 0, 5, 10, 20, 30, and 60 minutes, respectively, from the initial point while being passed through with humidified nitrogen;
- FIG. 9 represents the results of Differential Scanning Calorimetry on 7-(4-aminomethyl-3-methyloxylminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate anhydride and 3 hydrate;
- FIG. 10 represents the results of thermogravimetric analysis on 7-(4-aminomethyl-3-methyloxylminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-l,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate ⁇ 3 hydrate.
- the present invention relates to a novel quinoline(naphthyridine) carboxylic acid derivative having the following formula (I): ##STR12## and its pharmaceutically acceptable non-toxic salt, its physiologically hydrolyzable ester, solvate and isomer, in which
- R represents hydrogen, methyl or amino
- Q represents C--H, C--F, C--Cl, C--OH, C--CH 3 , C--O--CH 3 or N;
- R 1 represents cyclopropyl, ethyl, or phenyl which is substituted with one or more fluorine atom(s);
- R 2 represents one of the following a) through e):
- R 3 and R 4 independently of one another represent hydrogen or C 1 -C 3 alkyl or R 3 and R 4 together with a nitrogen atom to which they are attached can form a ring.
- the preferred compounds include those wherein Q represents C--H, C--F, C--Cl, C-OMe or N, R represents hydrogen or amino, R 1 represents cyclopropyl or 2,4-difluorophenyl, R 2 represents hydrogen, methyl, ethyl, isopropyl, t-butyl, phenyl, propargyl, homopropargyl, 2-fluoroethyl, benzyl, 2-fluorobenzyl or 2-cyanobenzyl, and R 3 and R 4 represent hydrogen.
- More preferred compounds of formula (I) include those wherein Q represents C--H, C--Cl, C--F or N, R represents hydrogen or amino, R 1 represents cyclopropyl, R 2 represents methyl, t-butyl, homopropargyl, 2-fluoroethyl, henzyl or 2-fluorobenzyl, and R 3 and R 4 represent hydrogen.
- the 4-carbon atom on which aminomethyl group is substituted is an asymmetric carbon atom and thus can be present in the form of R or S or a mixture of R abd S.
- the compound of formula (I) can be present in the form of syn- and anti-isomers depending on their geometric structure.
- the present invention also includes all of those geometric isomers and their mixtures.
- the compound of formula (I) according to the present invention can form a pharmaceutically acceptable non-toxic salt.
- Such salt includes a salt with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, etc., a salt with organic carboxylic acids such as acetic acid, trifluoroacetic acid, citric acid, maleic acid, oxalic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid or malic acid or with sulfonic acids such as methanesulfonic acid, para-toluenesulfonic acid, etc., and a salt with other acids which are generally known and conventionally used in the technical field of quinolone-based compounds.
- These acid-addition salts can be prepared according to a conventional conversion method.
- the present invention relates to the 7-(4-aminomethyl-3-methyloxylminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and its hydrate represented by the following formula (H), ##STR17## in which n denotes 0, 1, 1.5, 2, 2.5, 3, 3.5 or 4, having an improved bioavailability.
- the methanesulfonate and its hydrate as defined above exhibit the same potent antibacterial activity as the free form, also have desirable physicochemical properties such as excellent solubility, constant moisture content, etc. regardless of the ambient relative humidity.
- a pseudopolymorph differs from the original compound not in its chemical properties, such as pharmacological activity, but in its physical properties, such as crystallinity, hygroscopicity, melting point, solubility, solubilizing velocity, etc. So, the pseudopolymorph has been recognized as pharmaceutically important (see, Morris, K. P. et al., Int. J. Pharm., 108, 15-206 (1994)).
- the salt In the process of identifying the physicochemical properties of methanesulfonate, the salt has been found to exist as a stable hydrate when the number of water molecules contained in one molecule varies within a specific range.
- stability does not mean chemical stability but the difficulty of removing water molecules. That is, a stable hydrate neither loses the water molecules contained therein nor absorbs moisture over a wide range of ambient relative humidity. In contrast, moisture absorption by the anhydride varies greatly with the ambient relative humidity.
- the moisture content of the hydrate varies with the hydration number (n) of the hydrated molecule. Since the molecular weight of 7-(4-amino-methyl-3-methyloxylminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate is 485.5, the moisture content of the hydrate for n equal to 1, 1.5, 2, 2.5, 3, 3.5 or 4 is calculated to be 3.6%, 5%, 6.9%, 8.5%, 10.0%, 11.5% or 12.9%, respectively. However, the actual moisture content may differ from the calculated moisture content depending on differences in recrystallization conditions, drying conditions, etc. The range of the actual moisture content for each hydration number is shown in the following Table A.
- mixtures having a new moisture content by weight for example, a mixture of 1 hydrate and 1.5 hydrate having a moisture content of 2 to 6%; a mixture of 1.5 hydrate and 2 hydrate having a moisture content of 4 to 8%; a mixture of 2 and hydrate and 2.5 hydrate having a moisture content of 6 to 9%; a mixture of 2.5 hydrate and 3 hydrate having a moisture content of 8 to 11%; a mixture of 3 hydrate and 3.5 hydrate having a moisture content of 9 to 12%; or a mixture of 3.5 hydrate and 4 hydrate having a moisture content of 11 to 13%, can be obtained.
- the present invention also relates to a process for preparing the novel compound of formula (I).
- the compound of formula (I) can be prepared by reacting a compound of formula (II) with a compound of formula (III) or a salt thereof, as shown in the following reaction scheme 1.
- reaction scheme 1 ##STR18##
- R, R 1 , R 2 , R 3 , R 4 and Q are defined as previously described;
- X represents a halogen atom, preferably chlorine, bromine or fluorine.
- the compound of formula (I) according to the present invention can be prepared by stirring the compound of formula (II) and the compound of formula (III) in the presence of a solvent for 1 to 20 hours at the temperature between room temperature and 200° C. with the addition of a suitable base.
- the compound of formula (III) can be used in the form of a free compound or a salt with an acid such as hydrochloric acid, hydrobromic acid or trifluoroacetic acid.
- any solvent which does not adversely affect the reaction can be used.
- acetonitrile, dimethylformamide (DMF), dimethylsulfoxide (DMSO) pyridine, hexamethylphosphoramide (HMPA), N-methylpyrrolidinone, ethanol, and aqueous mixtures thereof can be used.
- This reaction is generally conducted in the presence of an acid acceptor.
- the reactant (III) is used in an excessive amount, for example, an equimolar amount to 10 times molar amount, preferably an equimolar amount to 5 times molar amount, with respect to the starting material (II).
- an equimolar amount to 10 times molar amount for example, an equimolar amount to 10 times molar amount, preferably an equimolar amount to 5 times molar amount, with respect to the starting material (II).
- the acid acceptor which can be preferably used in this reaction includes inorganic bases such as sodium hydrogen carbonate, potassium carbonate, etc., and organic bases such as triethylamine, diisopropylethylamine, pyridine, N,N-dimethylaniline, N,N-dimethylaminopyridine, 1,8-diazabicyclo 5.4.0! undec-7-ene(DBU), 1,4-diazabicyclo 2.2.2! octane(DABCO), etc.
- inorganic bases such as sodium hydrogen carbonate, potassium carbonate, etc.
- organic bases such as triethylamine, diisopropylethylamine, pyridine, N,N-dimethylaniline, N,N-dimethylaminopyridine, 1,8-diazabicyclo 5.4.0! undec-7-ene(DBU), 1,4-diazabicyclo 2.2.2! octane(DABCO), etc.
- the compound of formula (I) according to the present invention can also prepared by a method depicted in the following reaction scheme 2, in which a protecing group P is introduced into one of R 3 and R 4 of the compound of formula (III) wherein R 3 and R 4 are hydrogen to prepare the compound of formula (III') wherein the amino group is protected with P, the protected compound of formula (III') is reacted with the compound of formula (II) under the same condition as in the reaction scheme 1, and then the resulting compound of formula (I') is deprotected by removing the protecting group P to form the desired compound of formula (I).
- reaction scheme 2 In the above reaction scheme, R, R 1 , R 2 and Q are defined as previously described; and
- P represents an amino-protecting group.
- the compound of formula (III') can be used in the form of a free compound or a salt with hydrochloric acid, hydrobromic acid or trifluoroacetic acid, as in the compound of formula (III) used in the reaction scheme 1.
- protecting group P in the compound of formula (III') Any protecting group which is conventionally used in the field of organic chemistry and can be readily removed after the reaction without decomposition of the structure of the desired compound can be used as the suitable amino-protecting group P in the compound of formula (III').
- the specific example of protecting groups which can be used for this purpose includes formyl, acetyl, trifluoroacetyl, benzoyl, para-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, benzyloxycarbonyl, para-methoxybenzyloxycarbonyl, trichloroethoxycarbonyl, beta-iodoethoxycarbonyl, benzyl, para-methoxybenzyl, trityl, tetrahydropyranyl, para-nitrobenzoyl, etc.
- the amino-protecting group present in the resulting compound of formula (I') can be removed by hydrolysis, solvolysis or reduction depending on properties of the relevant protecting group.
- the compound of formula (II) is treated in a solvent in the presence or absence of an acid or base at the temperature of 0° to 130° C. to remove the protecting group.
- an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, etc.
- an organic acid such as acetic acid, trifluoroacetic acid, formic acid, toluenesulfonic acid, etc.
- a Lewis acid such as boron tribromide, aluminum chloride, etc.
- hydoxide of an alkali or alkaline earth metal such as sodium hydroxide, barium hydroxide, etc.
- an alkali metal carbonate such as sodium carbonate, calcium carbonate, etc.
- an alkali metal alkoxide such as sodium methoxide, sodium ethoxide, etc., or sodium acetate, and the like
- the reaction can be carried out in the presence of a solvent, for example, water or an organic solvent such as ethanol, tetrahydrofuran, dioxane, ethyleneglycol, acetic acid, etc., or a mixture of such organic solvent and water. If required, this reaction can also be practiced in the absence of any solvent.
- the protecting group is para-toluene-sulfonyl, benzyl, trityl, para-methoxybenzyl, benzyloxycarbonyl, para-methoxybenzyloxycarbonyl, trichloroethoxycarbonyl, betaiodoethoxycarbonyl and the like
- such groups can be effectively removed by means of a reduction.
- the reaction condition of the reduction for removing protecting group may be varied with properties of the relevant protecting group
- the reduction can be generally carried out with hydrogen gas stream in an inert solvent in the presence of a catalyst such as platinum, palladium, Raney nickel, etc., at the temperature of 10° to 100° C. or with metal sodium or metal lithium in ammonia at the temperature of -50° to -10° C.
- the compound of formula (II) used as the starting material in the present invention is a known compound and can be readily prepared according to a method known in the prior publication (see, J. M. Domagala, et al., J. Med. Chem. 34, 1142 (1991); J. M. Domagala, et al., J. Med. Chem. 31, 991 (1988); D. Bouzard, et al., J. Med. Chem. 35, 518 (1992)).
- the protecting groups P and P' independently of one another represent the same amino-protecting group as defined for P in connection with the compound of formula (III') and can be identical wraith or different from each other;
- a cyano ester 1! having a protected amino group can be reacted with sodium ethoxide in a solvent such as ethanol to obtain a 3-keto-4-cyanopyrrolidine 2!.
- the resulting cyanopyrrolidine 2! is reduced with hydrogen gas in the presence of a platinum catalyst to prepare an aminoalcohol 3!.
- the cyanopyrrolidine 2! may be reduced by means of other reductant to prepare the aminoalcohol 3!.
- the ketone and cyano groups can be reduced with lithium aluminumhydride(LAH), sodium borohydride-cobalt chloride complex(NaBH 4 --CoCl 3 ) or lithium borohydride(LiBH 4 ).
- the aminoalcohol 3! can be synthesized by reducing first the ketone group to a hydroxyl group by means of sodium borohydride(NaBH 4 ) and then reducing the cyano group by lithium aluminum hydride(LAH). Then, the amino group of the aminoalcohol 3! thus prepared is selectively protected to obtain a protected amine 4!, which is then treated with sulfur trioxide(SO 3 )-pyridine mixture in dimethylsulfoxide solvent (see, Parikh, J. R. and Doering, W. v. E. J. Am. Chem. Soc. 1967, 89, 5505), or oxidized with other oxidant, to prepare a ketone compound 5!. The resulting ketone compound 5!
- the ketone compound 5! is reacted with hydroxyamine to obtain the desired oxime compound 7! and the compound 7! is reacted with a suitable electrophilic compound of formula R 2 X which can introduce the desired R 2 group, in the presence of a base to prepare the oxime derivative of formula 6!, which is then deprotected by means of a suitable method selected depending on the kind of protecting group in the same manner as in the reaction scheme 3 to prepare the desired oxime compound (III-a).
- the amine compound 3! is treated with C 1 -C 3 aldehyde and then reduced to obtain a substituted amine compound 8! and the resulting amine compound 8! is treated with sulfur trioxide(SO 3 )-pyridine mixture in dimethylsulfoxide solvent, or oxidized with other oxidant, to obtain a ketone compound 9!.
- the resulting ketone compound 9! can be treated in the same manner as in the method for treating ketone compound 5! in the reaction schemes 3 and 4 to synthesize the desired compound of formula (III-b).
- the 7-(4-aminomethyl-3-methyloxylminopyrrolidin-1-yl) -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate can be prepared by adding the methanesulfonic acid to the corresponding quinolone carboxylic acid compound in an amount of 0.95 to 1.5 times molar amount with respect to the quinolone carboxylic acid compound, or by adding the same amount of the methanesulfonic acid which is already dissolved in a solvent to the quinolone carboxylic acid compound.
- solvents suitable for the above preparation include C 1 -C 4 haloalkanes, C 1 -C 8 alcohols and water, a solvent selected from the group consisting of dichloromethane, chloroform, 1,2-dichloroe- thane, methanol, ethanol, propanol, and water is preferred.
- the quinolone carboxylic acid compound in a solvent may be heated to dissolve the former before the methanesulfonic acid is added. If the quinolone carboxylic acid compoundsolution exists as a suspension, acid may be added to the suspension to obtain a thoroughly transparent solution.
- the resulting reaction mixture is stirred for 1 to 24 hours at a temperature of -10° to 40° C. or is allowed to stand, then the product is obtained as a solid according as the solubility of the product decreases.
- the methanesulfonate can also be obtained in a high yield by removing the solvent used under reduced pressure.
- the hydrates of the methanesulfonate of the present invention may easily be prepared by means of conventional methods well known in the art to which the present invention pertains. Particularly, the different hydrates may be prepared merely by changing recrystallization conditions.
- the present invention also provides an antibacterial composition
- an antibacterial composition comprising the novel compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof as an active component together with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier which can be used for this purpose may be solid or liquid.
- the solid or semi-solid pharmaceutical preparation in the form of powders, tablets, dispersible powders, capsules, cachets, suppositories and ointments may be prepared in which case solid carriers are usually used.
- the solid carrier which can be used is preferably one or more substances selected from the group consisting of diluents, flavouring agents, solubilizing agents, lubricants, suspending agents, binders, swelling agents, etc. or may be encapsulating substances.
- the micronized active component is contained in an amount of 5 or 10 to 70% in the carrier.
- the suitable solid carrier includes magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectine, dextrin, starch, gelatin, tragaganth, methylcellulose, sodium carboxymethylcellulose, low boiling wax, cocoa butter, etc. Because of their ease in administration, tablets, powders, cachets and capsules represent the most advantageous solid preparation for oral administration.
- the liquid preparation includes solutions, suspensions and emulsions.
- the injectable preparation for parenteral administration may be in the form of water or waterpropyleneglycol solution, of which isotonicity, pH and the like can be adjusted to be suited for the physiological condition of living body.
- the liquid preparation can also be prepared in the form of a solution in aqueous polyethyleneglycol solution.
- the aqueous solution for oral administration can be prepared by dissolving the active component in water and adding a suitable coloring agent, flavouring agent, stabilizer and thickening agent thereto.
- the aqueous suspension suitable for oral administration can be prepared by dispersing the micronized active component in viscous substances such as natural or synthetic gum, methylcellulose, sodium carboxymethylcellulose and other known suspending agent.
- Dosage unit forms of the preparation refer to physically discrete units suitable as unitary dosage, each unit containing a predetermined quantity of the active component calculated to produce the desired therapeutic effect.
- Such dosage unit form can be in the packaged form, for example, a tablet, a capsule or a powder filled in vial or ampule, or an ointment, gel or cream filled in tube or bottle.
- the amount of the active component contained in the dosage unit form can be varied, it can be generally adjusted within the range of 1 to 100 mg depending on the efficacy of the selected active component.
- the active compound of formula (I) of the present invention When used as a medicine for treatment of bacterial infections, it is preferably administered in an amount of about 6 to 14 mg per kg of body weight at the first stage.
- the administration dosage can be varied with the requirement of the subject patient, severity of the infections to be treated, the selected compound and the like.
- the preferred dosage suitable for a certain condition can be determined by a person skilled in this art according to a conventional manner.
- the therapeutic treatment is started from the amount less than the optimal dosage of the active compound and then the administration dosage is increased little by little until the optimal therapeutic effect is obtained.
- the total daily dosage can be divided into several portions and administered over several times.
- the compound of the present invention shows a potent and broad spectrum antibacterial activity against various pathogenic organisms including gram-positive and gram-negative strains.
- the antibacterial activity of the present compound against gram-negative strains is comparable to or higher than that of the known antibacterial agents (for example, ciprofloxacin), and particularly, the antibacterial activity of the present compound against gram-positive strains is far superior to that of the known antibacterial agents.
- the present compound also exhibits a very potent antibacterial activity against the strains resistant to the known quinolone compounds.
- the compound of the present invention has a high water-solubility and thus can be well absorbed in the living body, in comparison with the known quinolone compounds, to show a very high bioavailability.
- the biological half life of the present compound is far longer than that of the known quinolone compounds, and therefore, the present compound can be administered once a day to be suitably used as an antibacterial agent.
- the compound according to the present invention is less toxic, it can be effectively used for prophylaxis and treatment of diseases caused by bacterial infections in warmblooded animals including human being.
- Boc represents t-butoxycarbonyl.
- the reaction was continuously conducted for further one hour under refluxing with heating.
- the reaction solution was concentrated under reduced pressure and the residue was diluted with water and then washed with methylene chloride.
- the aqueous layer was adjusted with 1N HCl to pH 4 and extracted with ethyl acetate.
- the extract was dried over anhydrous magnesium sulfate and then filtered.
- the filtrate was concentrated to obtain a stoichiometric amount of the title compound in a crude state.
- the resulting solid complex was dissolved in 4 L of ammonia water and this solution was diluted with 8 L of water and then extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated and mixed with the mixture of 1.5 L of dioxane and 0.5 L of distilled water. 212 g of di-t-butoaycarbonyldicarbonate was added thereto and the whole mixture was stirred for 2 hours at room temperature. After the react ion is completed, the reaction mixture was concentrated under reduced pressure, diluted again with dichloromethane, washed with water, dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated and then purified with silica gel column chromatography (eluant: hexaneethyl acetate 2:1 by volume) to obtain 202 g (Yield: 64%) of the title compound.
- the resulting product was diluted with 200 of dioxane-water (2:1 by volume) and 12.3 g (0.056 mole) of di-t-butoxycarbonyldicarbonate was added portionwise thereto. The mixture was stirred for 30 minutes to complete the reaction, and then concentrated, diluted with ethyl acetate, washed with saturated saline, dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated and the residue was purified with column chromatography to obtain 12.3 g (Yield: 83%) of the title compound.
- Example 1 The same starting material as Example 1 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 1 to prepare the respective compounds listed in the following Table 8.
- Example 12 The same starting material as Example 12 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 12 to prepare the respective compounds listed in the following Table 9.
- Example 23 The same starting material as Example 23 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 23 to prepare the respective compounds listed in the following Table 10.
- Example 34 The same starting material as Example 34 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 34 to prepare the respective compounds listed in the following Table 11.
- Example 45 The same starting material as Example 45 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 45 to prepare the respective compounds listed in the following Table 12.
- Example 56 The same starting material as Example 56 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 56 to prepare the respective compounds listed in the following Table 13.
- Example 67 The same starting material as Example 67 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 67 to prepare the respective compounds listed in the following Table 14.
- Example 78 The same starting material as Example 78 was reacted with each of the compounds prepared in Preparations 19 to 28 according to the same procedure as Example 78 to prepare the respective compounds listed in the following Table 15.
- a sonicator filled with water was adjusted to 40° C. and was sealed with a lid. Then, a nitrogen introducing tube and a nitrogen excreting tube were connected to the vessel. When the pressure of the dried nitrogen introduced through the nitrogen introducing tube was adjusted to 20 psi, the relative humidity of the humidified nitrogen excreted through the excreting tube was more than 93%.
- 1 g of the anhydride having moisture content of about 2.5% prepared in Example 204 was introduced into a fritted filter and the humidified nitrogen prepared according to the above mentioned process was passed through. Samples were taken after 0, 5, 10, 20, 30, and 60 minutes, respectively, and the moisture content with the lapse of time was measured. From the results shown in FIG. 8, it can be seen that moisture content of about 10% is constantly maintained when the humidifying procedure is carried out over 30 minutes.
- the X-ray diffraction pattern of the humidified sample was identical to that the 3 hydrate obtained after recrystallization.
- the title compound can be prepared by two different processes.
- Example 204 1.0 g of the anhydride prepared in Example 204 was dissolved in 17 ml of a mixture of water and acetone (10/7, v/v). The solvent was slowly evaporated in darkness leaving 0.8 g of the title compound as a solid.
- Example 204 In the second process, 5.0 g of the anhydride prepared in Example 204 was added to 10 ml of water and the mixture was heated to about 45° C. in order to dissolve the anhydride. After 20 ml of ethanol was added thereto, the resulting solution was stirred and then allowed to stand to form a solid. The solid thus produced was filtered and dried under nitrogen flow to obtain 2.6 g of the title compound.
- the antibacterial activity of the compounds according to the present invention was determined by measuring their minimum inhibitory concentrations (MIC, ⁇ g/ml), against standard strains, clinically isolated strains and strains resistant to some antibacterial agents.
- the known antibacterial compounds, ofloxacin and ciprofloxacin were used as the comparative agents.
- the minimum inhibitory concentration could be determined by diluting the test compounds according to a two-times dilution method, dispersing the diluted test compounds in Mueller-Hinton agar medium and then inoculating 5 ⁇ l of the standard strain having 10 7 CFU per ml to the medium, which is then incubated for 18 hours at 37° C. The measured results are described in the following Table 25.
- the pharmacokinteic property parameters of the compounds of the present invention were determined using SD rats (male), weighing about 230 ⁇ 10 g. Specifically, the test compounds of the present invention were administered in an amount of 20 mg/kg of body weight to test rats via femoral veins. Then, bloods were collected at certain intervals after administration of the test compounds from femoral veins and analyzed by means of Agar Well Method to measure the blood concentration of the test compounds from which pharmacokinetic parameters, half life (T 1/2 ), and AUC (area under the curve), were calculated. The obtained results are described in the following Table 26.
- test solution containing the compounds in various concentrations were orally administered to ICR male mouse in an amount of 10 ml per kg of body weight.
- LD 50 value mg/kg
- the moisture adsorption velocity and the equilibrium moisture content of the anhydride prepared in Example 203 were determined by means of an automatic moisture adsorption analyzer (MB 300 G Gravimetric Sorption Analyzer). This instrument produces a specific relative humidity at a specific temperature and continuously records the weight change of a sample due to adsorption or desorption of moisture as measured by a micro balance inside the instrument. 16 mg of the anhydride sample was loaded on the micro balance and the moisture contained in the sample was removed under a dry nitrogen stream at 50° C. A weight change of less than 5 ⁇ g per 5 minutes was the criterion for complete dryness.
- FIG. 1 shows the moisture adsorption velocity, that is, the time required for the sample to reach equilibrium at each relative humidity from 0 to 95% at 5% intervals. Initial moisture adsorption proceeded very speedily at each relative humidity tested. In most cases, the equilibrium was reached within 2 hours.
- FIG. 2 shows the weight increment(%) at each relative humidity, that is, the equilibrium moisture content. It is clear from FIG. 2 that the equilibrium moisture content is dependent upon the relative humidity.
- METTLER TOLEDO DSC821e and METTLER TOLEDO STARe System were used for the Differential Scanning Calorimetry. 3.7 mg of sample was weighed into the aluminum pan, which was then press sealed with an aluminum lid. After three tiny needle holes were made on the lid, the sample was tested by heating from normal temperature to 250° C. at a rate of 10° C./min. As can be seen from FIG. 9, the endothermic peak due to the vaporization of the water molecules contained in the 3 hydrate begins at around 50° C. and the exothermic peak due to the thermal decomposition was observed at around 180° to 220° C. In contrast, the anhydride showed only an exothermic peak due to thermal decomposition at around 185° to 220° C. without any endothermic peak.
- thermogravimetric analysis SEIKO TG/DTA220 was used. 3.8 mg of the sample was weighed into an aluminum pan and was heated from normal temperature to 250° C. at a rate of 10° C./min according to the temperature raising program. As can be seen from FIG. 10, weight decrement was observed at the temperature range of endothermic peak, the extent of which corresponds to the moisture content determined by Karl-Fisher method (Mettler Toledo DL37KF Coulometer).
- Example 204 After 50 mg of the anhydride in Example 204, the 3 hydrate in Example 205, and the 1.5 hydrate in Example 206 were each thinly spread on the sample holder, X-ray diffraction analyses (35 kV ⁇ 20 mA Rigaku Gergeflex D/max-IIIC) were performed under the conditions listed below.
- the methanesulfonate shows a water solubility superior to that of the tartarate, the sulfurate, and the p-toluenesulfonate as well as the free form. Therefore, it is identified that the methanesulfonate has a desirable solubility as well as an excellent antibacterial activity.
- Example 204 In order to determine the antibacterial activitiers of the E- and Z-isomner of the compound 180 which were separated in Example 203, and of 7- (4-aminomethyl-3-methyloxylminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate prepared in Example 204, in vitro antibacterial activities of them were measured using agar medium dilution method. The results were as described in the following Tables 31 and 32.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
TABLE A
______________________________________
Moisture Content according to Hydration Number
Hydration Number (n)
Moisture Content (%)
______________________________________
1 2-4
1.5 4-6
2 6-8
2.5 8-9
3 9-11
3.5 11-12
4 12-13
______________________________________
TABLE 1 __________________________________________________________________________Preparations 8 to 17 FAB Prep. R.sub.2 NMR (CDCl.sub.3), δ (ppm) MS (M + H) __________________________________________________________________________ 8 4-nitrobenzyl 8.2(2H, m), 7.4(2H, m), 5.2(2H, s), 4.9(1H, 465 s), 4.2(2H, m), 3.8(1H, m), 3.5-3.2(3H, m), 3.0(1H, m), 1.5(18H, s) 9 4-methoxybenzyl 7.3(2H, m), 6.9(2H, m), 5.0(2H, s), 4.9(1H, 450 s), 4.1(2H, m), 3.8(3H, s), 3.75(1H, m), 3.5-3.0(4H, m), 1.45(18H, s) 10 4-fluorobenzyl 7.3(2H, m), 7.0(2H, m), 5.0(2H, s), 4.8(1H, 438 br), 4.2(2H, m), 3.9(1H, m), 3.4(3H, m), 3.0(1H, m), 1.46(18H, s) 11 4-t-butylbenzyl 7.4-7.3(4H, m), 5.1(2H, s), 5.0(1H, s), 476 4.1(2H, m), 3.8(1H, m), 3.6-3.0(4H, m), 1.45(18H, s), 1.3(9H, s) 12 2-cyanobenzyl 7.8-7.3(4H, m), 5.3(2H, s), 5.0(1H, bs), 445 4.2(2H, s), 3.9(1H, m), 3.6-3.2(3H, m), 3.0(1H, s), 1.5(18H, s) 13 3-pyridylmethyl 8.6(2H, m), 7.7(1H, m), 7.3(1H, m), 5.1(2H, 421 s), 4.9(1H, s), 4.1(2H, m), 3.8(1H, m), 3.6-3.2(3H, m), 3.0(1H, m), 1.5(18H, s) 14 7.4(2H, m), 6.5(1H, m), 4.9(2H, s), 4.9(1H, s), 4.1(2H, m), 3.8(2H, m), 3.2(3H, m), 1.5(18H, s) 410 15 ##STR30## 7.7(2H, m), 7.2(1H, m), 5.5(1H, s), 5.0(1H, s), 4.2(2H, m), 3.8(1H, m), 3.6-3.1(4H, m), 1.5(18H, 495 16 ##STR31## 6.9(3H, m), 6.0(2H, m), 5.0(3H, m), 4.1(2H, m), 3.8(1H, m), 3.6-3.2(3H, m), 3.0(1H, m), 1.5(18H, 464 17 ##STR32## 7.3-7.0(3H, m), 6.8(1H, s), 5.1(1H, s), 4.2(2H, m), 3.8(1H, m), 3.5-3.0(4H, m), 1.6-1.4(27H, 496 __________________________________________________________________________
TABLE 2
__________________________________________________________________________
Preparations 19 to 28
FAB
Prep.
R.sub.2 NMR (CDCl.sub.3), δ (ppm)
MS (M + H)
__________________________________________________________________________
19 4-nitrobenzyl 10.3-10.1(2H, s), 8.3(3H, s), 8.2(2H, d),
265
7.7(2H, d), 5.3(2H, s), 4.1(2H, m), 3.7(1H,
m), 3.4(2H, m), 3.1(2H, m)
20 4-methoxybenzyl
10.2-10.0(2H, s), 8.4(3H, s), 7.3(2H, d),
250
6.9(2H, d), 5.0(2H, s), 3.9(2H, m), 3.73(3H,
s), 3.7(1H, m), 3.4(2H, m), 3.1(2H, m)
21 4-fluorobenzyl
10.2(2H, s), 8.4(3H, s), 7.3(2H, m), 7.2(2H,
238
m), 5.1(2H, s), 3.9(2H, m), 3.7(1H, m),
3.4(2H, m), 3.1(2H, m)
22 4-t-butylbenzyl
10.2(2H, s), 8.4(3H, s), 7.4-7.3(4H, m),
276
5.1(2H, s), 3.9(2H, m), 3.7(1H, m), 3.2
(2H, m), 3.1(2H, m), 1.3(9H, s)
23 2-cyanobenzyl 10.2-10.0(2H, s), 8.2(3H, s), 7.9-7.5(4H,
245
m, 5.3(2H, s), 4.0(2H, m), 3.7(1H, m),
3.2(2H, m), 3.1(2H, m)
24 3-pyridylmethyl
10.3(1H, s), 10.1(1H, s), 8.9(1H, s), 8.8
221
(1H, m), 8.5(1H, d), 8.4(3H, m), 8.0(1H, m),
5.4(2H, s), 4.0(2H, m), 3.7(1H, m), 3.4
(2H, m), 3.1(2H, m)
25
10.3(2H, s), 8.4(3H, s), 7.6(1H, s), 6.4(1H, s), 5.0(2H,
s), 4.0(2H, m), 3.8(1H, m), 3.4(2H, m), 3.1(2H,
210
26
##STR35## 10.3(2H, s), 8.3(3H, s), 8.1(1H, m), 7.9 (1H, m),
7.4(1H, m), 5.5(2H, s), 4.1(2H, m), 3.9(1H, m), 3.14(2H,
m), 3.1(2H, m) 295
27
##STR36## 10.2(2H, s), 8.3(3H, s), 7.0(3H, m), 6.3 (2H, s),
5.3(2H, m), 4.1(2H, m), 3.9(1H, m), 3.4-3.2(2H, m),
3.1(2H, m) 264
28
##STR37## 10.3-10.2(2H, s), 8.4(3H, s), 8.0-7.3(3H, m), 7.0(1H,
s), 4.2(2H, m), 3.8(1H, m), 3.5-3.2(3H, m), 3.0(1H,
296
__________________________________________________________________________
TABLE 3 __________________________________________________________________________Preparations 31 to 36 FAB Prep. R.sub.2 .sup.1 H NMR (CDCl.sub.3), δ (ppm) MS (M + H) __________________________________________________________________________ 31 isopropyl 5.0(1H, br), 4.1(2H, s), 4.0(1H, m), 3.4 372 (1H, m), 3.55-3.25(3H, m), 3.0(1H, m), 1.55(18H, s), 1.0(6H, d) 32 cyclobutyl 4.7(1H, m), 4.2(2H, s), 3.8(1H, m), 3.4(1H, 384 m), 3.3(2H, m), 3.0(1H, m), 2.3(2H, m), 2.1 (2H, m), 1.8(1H, m), 1.6(1H, m), 1.5(18H, s) 33 cyclopentyl 4.7(1H, m), 4.1(2H, m), 3.7(1H, m), 398 3.4(1H, m), 3.3(2H, m), 3.0(1H, m), 1.8(4H, m), 1.7(4H, m), 1.6(18H, s) 34 5.0-4.8(1H, m), 4.3-3.7(6H, m), 3.3(2H, m), 3.0(1H, m), 2.1(2H, m), 1.5(18H, s), 1.3(2H, m) 400 35 cyclopropyl- 5.1(1H, br), 4.1(2H, m), 3.9(2H, m), 3.8(1H, 384 methyl m), 3.5(1H, m), 3.3(2H, m), 3.0(1H, m), 1.5 (18H, s), 1.1(1H, m), 0.6(2H, s), 0.3(2H, s) 36 isobutyl 5.05(1H, br), 4.15(2H, s), 4.1(2H, d), 386 3.6(2H, m), 3.3(1H, m), 3.0(2H, m), 2.5(1H, m), 1.5(18H, s), 1.05(6H, d) __________________________________________________________________________
TABLE 4
______________________________________
Preparations 38 and 39
FAB
Prep.
R.sub.2 .sup.1 H NMR (CDCl.sub.3), δ (ppm)
MS (M + H)
______________________________________
38 methoxymethyl
5.15-4.9(3H), 4.15(2H, m), 3.75
374
(1H, m), 3.5-3.2(5H), 3.0(1H, m),
1.5(18H, s)
39 2-chloroethyl
4.9(1H, m), 4.30(2H, t), 4.1(2H,
392
s), 3.7(3H, m), 3.6(1H, m), 3.5-
3.0(3H, m), 1.45(18H, s)
______________________________________
TABLE 5 __________________________________________________________________________Preparations 41 to 50 FAB Prep. R.sub.2 .sup.1 H NMR (CDCl.sub.3), δ (ppm) MS (M + H) __________________________________________________________________________ 41 CH.sub.2 CH.sub.2 C CH 10.1-9.8(2H, br), 8.2(3H, br), 4.3(2H, t), 182 4.0(2H, s), 3.7(1H, m), 3.6-3.2(3H, m), 3.0(1H, m), 2.8(1H, s), 2.6(2H, t) 42 isopropyl 10.1-9.8(2H, br), 8.3(3H, br), 4.4(1H, m), 172 3.9(2H, d), 3.7(1H, m), 3.3(2H, s), 3.1(2H, m), 1.2(6H, d) 43 cyclobutyl 10.2-9.8(2H, br), 8.2(3H, br), 4.8(1H, m), 184 4.3(2H, s), 3.7(1H, m), 3.6-3.2(3H, m), 3.0(1H, m), 1.8(2H, m), 1.7(2H, m), 1.5(1H, m), 1.45(1H, m) 44 cyclopentyl 10.2-9.8(2H, br), 8.2(3H, br), 4.7(1H, m), 198 4.3(2H, s), 3.8(1H, m), 3.3(1H, m), 3.2(3H, m), 1.8(4H, m), 1.6(2H, m), 1.5(2H, m) 45 10.1-9.8(2H, br), 8.3(3H, s), 4.1-3.6 (10H, m), 3.2(2H, s), 2.2-1.9(2H, m) 200 46 cyclopropyl- 10.1-9.8(2H, br), 8.3(3H, s), 4.0-3.8 184 methyl (4H, m), 3.65(1H, m), 3.4(2H, m), 3.1(2H, m), 1.1(1H, m), 0.5(2H, d), 0.2(2H, d) 47 isobutyl 10.3-9.9(2H, br), 8.4(3H, br), 3.9-3.8 186 (4H, m), 3.65(1H, m), 3.3(2H, s), 3.1(2H, m), 1.9(1H, m), 0.85(6H, d) 48 propargyl 10.0(1H, m), 8.3(2H, m), 4.8(2H, s), 168 4.0(2H, m), 3.7(1H, m), 3.6(1H, s) 3.4(2H, m), 3.1(2H, s) 49 methoxymethyl 10-9.6(2H, br), 8.2(3H, br), 5.1(2H, dd) 174 4.1-3.8(2H, m), 3.7(1H, m), 3.3-3.0(4H, m) 50 2-chloroethyl 10-9.7(2H, br), 8.2(3H, br), 4.3(2H, t), 192 4.0(2H, m), 3.8(2H, t), 3.7(1H, m), 3.4(2H, m), 3.2(1H, m), 3.1(2H, m) __________________________________________________________________________
TABLE 6 ______________________________________Preparations 52 and 53 FAB Prep. R.sub.2 .sup.1 H NMR (CDCl.sub.3), δ (ppm) MS (M + H) ______________________________________ 52 phenyl 7.3(5H, m), 4.97(1H, bs), 3.8-2.8 406 (7H, m), 1.40(18H, s) 53 --CH.sub.2 CH.sub.3 5.0(1H, bs), 3.8-2.8(7H, m), 1.42 358 (18H, s), 1.41(18H, s), 1.38(3H, t) ______________________________________
TABLE 7 ______________________________________Preparations 55 to 57 FAB Prep. R.sub.2 .sup.1 H NMR (CDCl.sub.3), δ (ppm) MS (M + H) ______________________________________ 55 --H 4.1-3.2(7H, m) 130 56 Ph 7.2-7.4(5H, m), 4.1-3.2(7H, m) 206 57 --CH.sub.2 CH.sub.3 4.2-3.1(9H, m), 1.3(3H, t) 158 ______________________________________
TABLE 8
__________________________________________________________________________
Examples 2 to 11
##STR50##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(min)
(%)
__________________________________________________________________________
##STR51## 8.73(1H, s), 8.05(1H, d), 7.30 (2H, d), 6.98(2H, d),
5.10(2H, s), 4.61(2H, s), 4.25(1H, m), 3.90(1H, m),
3.80(3H, s), 3.70 (1H, m), 3.00(3H, m), 1.26(2H, m),
1.07(2H, m) CDCl.sub.3
496 10 75
3
##STR52## 8.75(1H, s), 8.05(1H, d), 7.45 (2H, d), 7.30(2H, d),
5.15(2H, s), 4.62(2H, s), 4.25(1H, m), 3.85(1H, m),
3.75(1H, m), 3.10 (1H, m), 2.98(2H, m), 1.35(9H, s),
1.25(2H, m), 1.09(2H, m)
CDCl.sub.3
522 15 76
4
##STR53## 8.68(1H, s), 8.00(1H, d), 7.35 (2H, m), 7.10(2H, m),
5.08(2H, s), 4.59(2H, s), 4.20(1H, m), 3.95(1H, m),
3.81(1H, m), 3.00 (3H, m), 1.23(2H, m),
CDCl.sub.3)
484 15 80
5
##STR54## 8.59(1H, s), 8.21(2H, d), 8.06 (1H, s), 7.64(2H, d),
5.29(2H, s), 4.68(2H, s), 4.20(1H, m), 3.95(1H, m),
3.85(1H, m), 3.10 (1H, m), 2.80(2H, m), 1.18(2H, m),
1.10(2H, m) DMSO 511 10 76
6
##STR55## 8.58(1H, s), 8.05(1H, d), 7.92- 7.42(4H, m), 5.28(2H, s),
.65(2H, s), 4.20(1H, m), 3.95 (1H, m), 3.78(1H, m),
3.10(1H, m), 2.80(2H, m), 1.20(2H, m), 1.09(2H,
DMSO 491 20 82
7
##STR56## 8.74(1H, s), 8.10(1H, d), 6.92 (3H, m), 6.10(2H, s),
5.10(2H, s), 4.75(2H, s), 4.30(1H, m), 3.95(1H, m),
3.85(1H, m), 3.15 (1H, m), 3.10(2H, m), 1.28(2H, m),
1.09(2H, m) CDCl.sub.3
510 25 79
8
##STR57## 8.60(1H, d), 8.57(1H, s), 8.52 (1H, d), 8.03(1H, d),
7.80(1H, d), 7.41(1H, q), 5.18(2H, s), 4.65(2H, s),
4.17(1H, m), 3.94 (1H, m), 3.75(1H, m), 3.30(2H, m),
3.04(1H, m), 2.81(1H, m), 2.73(1H, m), 1.30-1.00(4H,
DMSO-d.sub.6
467 90 70
9
##STR58## 8.82(1H, s), 8.05(1H, d), 7.51 (1H, d), 7.45(1H, m),
6.5(1H, s), 5.02(2H, m), 4.5(2H, m), 4.20(1H, m),
3.95(1H, m), 3.70 (1H, m), 3.00(1H, m), 2.80(1H, m),
2.70(1H, m), 1.00(4H, m)
DMSO 456 15 69
10
##STR59## 8.58(1H, s), 8.00(1H, d), 7.10 (3H, m), 6.72(1H, s),
4.80(2H, s), 4.20(1H, m), 3.95(1H, m), 3.85(1H, m),
3.10(1H, m), 2.95 (2H, m), 1.07(4H, m)
DMSO 542 20 65
11
##STR60## 8.76(1H, s), 8.20(1H, m), 8.02 (1H, d), 7.89(1H, m),
7.40(1H, m), 5.60(2H, s), 4.78(2H, m), 4.45(1H, m),
3.85(1H, m), 3.70 (1H, m), 3.10(2H, m), 1.30(2H, m),
1.15(2H. m) DMSO 541 25 73
__________________________________________________________________________
TABLE 9
__________________________________________________________________________
Examples 13 to 22
##STR62##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
13
##STR63## 8.6(1H, s), 7.8(1H, d), 7.2(3H, d), 6.9(2H, d), 5.1(2H,
s), 4.4 (2H, s), 3.9(1H, m), 3.8(1H, m), 3.7(3H, s),
3.65(1H, m), 3.0 (1H, m), 2.9-2.7(2H, m), 1.3- 1.1(4H,
DMSO-d.sub.6
495 2 60
14
##STR64## 8.6(1H, s), 7.8(1H, d), 7.4(2H, d), 7.3(3H, m), 5.1(2H,
s), 4.4 (2H, s), 3.9(1H, m), 3.8(1H, m), 3.7(1H, m),
3.0(1H, m), 2.9-2.7 (2H, m), 1.4(9H, s), 1.3-1.1 (4H,
DMSO-d.sub.6
521 2 65
15
##STR65## 8.6(1H, s), 7.8(1H, d), 7.4(2H, m), 7.2(3H, m), 5.1(2H,
s), 4.4 (2H, s), 3.9(1H, m), 3.8(1H, m), 3.7(1H, m),
3.0(1H, m), 2.9-2.7 (2H, m), 1.3-1.1(4H,
DMSO-d.sub.6
483 4 67
16
##STR66## 8.6(1H, s), 8.2(2H, d), 7.8(1H, d), 7.6(2H, d). 7.2(1H,
d), 5.3 (2H, s), 4.4(2H, s), 3.9(1H, m), 3.8(1H,m),
3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 1.3-1.1 (4H,
DMSO-d.sub.6
510 3 58
17
##STR67## 8.6(1H, s), 7.9-7.4(5H, m), 7.2 (1H, d, ), 5.3(2H, s),
4.4(2H, s), 3.9(1H, m), 3.8(1H, m), 3.7(1H, m), 3.0(1H,
m), 2.9-2.7(2H, m), 1.3-1.1(4H, m)
DMSO-d.sub.6
490 4 55
18
##STR68## 8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 6.9(3H, m), 6.1(2H,
s), 5.1 (2H, s), 4.4(2H, s), 3.9(1H, m), 3.8(1H, m),
3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 1.3-1.1 (4H,
DMSO-d.sub.6
509 4 71
19
##STR69## 8.6(3H, m), 7.8(2H, m), 7.4(1H, q), 7.2(1H, d), 5.2(2H,
s), 4.4 (1H, m), 3.9(1H, m), 3.8(1H, m), 3.7(1H, m),
3.0(1H, m), 2.9-2.7 (2H, m), 1.3-1.1(4H,
DMSO-d.sub.6
466 4 53
20
##STR70## 8.6(1H, s), 7.8(1H, d), 7.5(2H, m), 7.2(1H, d), 6.5(1H
,m), 5.0 (2H, m), 4.4(1H, m), 3.9(1H, m), 3.8(1H, m),
3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 1.3-1.1 (4H,
DMSO-d.sub.6
455 4 60
21
##STR71## 8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 7.1(3H, m), 6.7(1H,
s), 4.4 (1H, m), 3.9(1H, m), 3.8(1H, m), 3.7(1H, m),
3.0(1H, m), 2.9-2.7 (2H, m), 1.3-1.1(4H,
DMSO-d.sub.6
541 4 50
22
##STR72## 8.6(1H, s), 8.2(1H, m), 7.9-7.8 (2H, m), 7.4(1H, m),
7.2(1H, d), 5.6(2H, s), 4.4(1H, m), 3.9(1H, m), 3.8(1H,
m), 3.0(1H, m), 2.9- 2.7(2H, m), 1.3-1.1(4H,
DMSO-d.sub.6
540 4 70
__________________________________________________________________________
TABLE 10
__________________________________________________________________________
Examples 24 to 33
##STR74##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
24
##STR75## 8.6(1H, s), 7.7(1H, d), 7.2(2H, d), 6.9(2H, d), 5.1(2H,
s), 4.3 (2H, s), 4.1(1H, m), 3.9(1H, m), 3.8(1H, m),
3.7(3H, s), 2.9(1H, m), 2.8-2.7(2H, m), 1.15(4H,
DMSO-d.sub.6
513 2 75
25
##STR76## 8.6(1H, s), 7.7(1H, d), 7.5(2H, m), 7.1(2H, m), 5.1(2H,
s), 4.3 (2H, s), 4.1(1H, m), 3.9(1H, m), 3.8(1H, m),
2.9(1H, m), 2.8-2.7 (2H, m), 1.4(9H, s), 1.15(4H,
DMSO-d.sub.6
539 4 70
26
##STR77## 8.6(1H, s), 7.7(1H, d), 7.3(2H, m), 7.1(2H, m), 5.1(2H,
s), 4.3 (2H, s), 4.1(1H, m), 3.9(1H, m), 3.8(1H, m),
2.9(1H, m), 2.8-2.7 (2H, m), 1.15(4H, m)
DMSO-d.sub.6
501 4 80
27
##STR78## 8.6(1H, s), 8.2(2H, d), 7.7(1H, d), 7.6(2H, d), 5.3(2H,
s), 4.3 (2H, s), 4.1(1H, m,), 3.9(1H, m), 3.8(1H, m),
2.9(1H, m), 2.8-2.7 (2H, m), 1.15(4H, m)
DMSO-d.sub.6
528 3 68
28
##STR79## 8.6(1H, s), 7.9-7.4(5H, m), 5.3 (2H, s), 4.3(2H, s),
4.1(1H, m), 3.9(1H, m), 3.8(1H, m), 2.9(1H, m),
2.8-2.7(2H, m), 1.15(4H, m)
DMSO-d.sub.6
508 2 70
29
##STR80## 8.6(1H, s), 7.7(1H, d), 7.0(3H, m), 6.1(2H, s), 5.1(2H,
s), 4.3 (2H, s), 4.1(1H, m), 3.9(1H, m), 3.8(1H, m),
2.9(1H, m), 2.8-2.7 (2H, m), 1.15(4H, m)
DMSO-d.sub.6
527 3 69
30
##STR81## 8.6(3H, m), 7.8(1H, d), 7.7(1H, d), 7.4(1H, q), 5.3(2H,
s), 4.3 (2H, s), 4.1(1H, m), 3.9(1H, m), 3.8(1H, m),
2.9(1H, m), 2.8-2.7 (2H, m), 1.15(4H, m)
DMSO-d.sub.6
484 3 58
31
##STR82## 8.6(1H, s), 7.7(1H, d), 7.5(2H, m), 6.5(1H, m), 5.0(2H,
m), 4.3 (2H, s), 4.1(1H, m), 3.9(1H, m), 3.8(1H, m),
2.9(1H, m), 2.8-2.7 (2H, m), 1.15(4H, m)
DMSO-d.sub.6
473 3 70
32
##STR83## 8.6(1H, s), 7.7(1H, d), 7.1(3H, m), 6.6(1H, s), 4.3(2H,
s), 4.1 (1H, m), 3.9(1H, m), 3.8(1H, m), 2.9(1H, m),
2.8-2.7(2H, m), 1.15(4H, m)
DMSO-d.sub.6
559 4 59
33
##STR84## 8.6(1H, s), 8.3(1H, m), 7.9(1H, m), 7.7(1H, d), 7.4(1H,
m), 5.6 (2H, s), 4.3(2H, s), 4.1(1H, m), 3.9(1H, m),
3.8(1H, m), 2.9(1H, m), 2.8-2.7(2H, m), 1.15(4H,
DMSO-d.sub.6
558 4 60
__________________________________________________________________________
TABLE 11
__________________________________________________________________________
Examples 35 to 44
##STR86##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
35
##STR87## 8.7(1H, s), 7.9(1H, d), 7.3(2H, d), 7.0(2H, d), 5.1(2H,
s), 4.4 (2H, s), 4.3(1H, m), 3.8(1H, m), 3.7(3H, s),
3.0(1H, m), 2.9-2.6 (2H, s), 1.2-0.9(4H,
DMSO-d.sub.6
529 3 63
36
##STR88## 8.7(1H, s), 7.9(1H, d), 7.5(2H, d), 7.3(2H, d), 5.2(2H,
s), 4.4 (2H, s), 4.3(1H, m), 3.8(1H, m), 3.0(1H, m),
2.9-2.7(2H, m), 1.4 (9H, s), 1.2-0.9(4H,
DMSO-d.sub.6
555 3 73
37
##STR89## 8.7(1H, s), 7.9(1H, d), 7.4(2H, m), 7.1(2H, m), 5.1(2H,
s), 4.4 (2H, s), 4.3(1H, m), 3.8(1H, m), 3.0(1H, m),
2.9-2.7(2H, m), 1.2-0.9(4H, m)
DMSO-d.sub.6
517 2 80
38
##STR90## 8.7(1H, s), 8.3(2H, d), 7.9(1H, d), 7.7(2H, d), 5.4(2H,
s), 4.4 (2H, s), 4.3(1H, m), 3.8(1H, m), 3.0(1H, m),
2.9-2.7(2H, m), 1.2-0.9(4H, m)
DMSO-d.sub.6
544 4 63
39
##STR91## 8.7(1H, s), 7.9-7.4(5H, m), 5.3 (2H, s), 4.4(2H, s),
4.3(1H, m), 3.8(1H, m), 3.0(1H, m), 2.9-2.7 (2H, m),
1.2-0.9(4H, m) DMSO-d.sub.6
524 4 70
40
##STR92## 8.7(1H, s), 7.9(1H, d), 7.0(3H, m), 6.1(2H, s), 5.1(2H,
s), 4.4 (2H, s), 4.3(1H, m), 3.8(1H, m), 3.0(1H, m),
2.9-2.7(2H, m), 1.2-0.9(4H, m)
DMSO-d.sub.6
543 2 67
41
##STR93## 8.7(1H, s), 7.9(1H, d), 8.6(2H, m), 7.8(1H, d), 7.4(1H,
q), 5.2 (2H, s), 4.4(2H, s), 4.3(1H, m), 3.8(1H, m),
3.0(1H, m), 2.9-2.7 (2H, m), 1.2-0.9(4H,
DMSO-d.sub.6
500 4 60
42
##STR94## 8.7(1H, s), 7.9(1H, d), 7.5(2H, m), 6.5(1H, m), 5.0(2H,
m), 4.4 (2H, s), 4.3(1H, m), 3.8(1H, m), 3.0(1H, m),
2.9-2.7(2H, m), 1.2-0.9(4H, m)
DMSO-d.sub.6
489 2 62
43
##STR95## 8.7(1H, s), 7.9(1H, d), 7.1(3H, m), 6.7(1H, s), 4.4(2H,
s), 4.3 (1H, m), 3.8(1H, m), 3.0(1H, m), 2.9-2.6(2H, m),
1.2-0.9(4H, m) DMSO-d.sub.6
575 4 60
44
##STR96## 8.7(1H, s), 8.2(1H, m), 7.9(2H, m), 7.4(1H, m), 5.6(2H,
s), 4.4 (2H, s), 4.3(1H, m), 3.8(1H, m), 3.0(1H, m),
2.9-2.7(2H, m), 1.2-0.9(4H, m)
DMSO-d.sub.6
574 4 76
__________________________________________________________________________
TABLE 12
__________________________________________________________________________
Examples 46 to 55
##STR98##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
46
##STR99## 8.8(1H, s), 7.8(1H, d), 7.4(2H, d), 7.1(2H, d), 5.2(2H,
s), 4.6 (2H, s), 4.3(1H, m), 4.1(1H, m), 3.9(1H, m),
3.8(3H, s), 3.0(1H, m), 2.9-2.7(2H, m), 2.7(3H, s),
1.3(2H, m), 0.95(2H, m)
DMSO-d.sub.6
525 17 38
47
##STR100## 8.8(1H, s), 7.8(1H, d), 7.6(2H, d), 7.4(2H, d), 5.3(2H,
s), 4.6 (2H, s), 4.3(1H, m), 4.1(1H, m), 3.9(1H, m),
3.0(1H, m), 2.9-2.7 (2H, m), 2.7(3H, s), 1.5(9H, s),
1.3(2H, m), 0.95(2H, m)
DMSO-d.sub.6
551 17 34
48
##STR101## 8.8(1H, s), 7.8(1H, d), 7.5(2H, m), 7.2(2H, m), 5.2(2H,
s), 4.6 (2H, s), 4.3(1H, m), 4.1(1H, m), 3.9(1H, m),
3.0(1H, m), 2.9-2.7 (2H, m), 2.7(3H, s), 1.3(2H, m),
0.95(2H, m) DMSO-d.sub.6
513 17 40
49
##STR102## 8.8(1H, s), 8.3(2H, d), 7.8(1H, d), 7.7(2H, d), 5.4(2H,
s), 4.6 (2H, s), 4.3(1H, m), 4.1(1H, m), 3.9(1H, m),
3.0(1H, m), 2.9-2.7 (2H, m), 2.7(3H, s), 1.3(2H, m),
0.95(2H, m) DMSO-d.sub.6
540 17 37
50
##STR103## 8.8(1H, s), 8.0-7.5(5H, m), 5.4 (2H, s), 4.6(2H, s),
4.3(1H, m), 4.1(1H, m), 3.9(1H, m), 3.0(1H, m),
2.9--2.7(2H, m), 2.7(3H, s), 1.3(2H, m), 0.95(2H,
DMSO-d.sub.6
520 17 42
51
##STR104## 8.8(1H, s), 7.8(1H, d), 7.0(3H, m), 6.2(2H, s), 5.2(2H,
s), 4.6 (2H, s), 4.3(1H, m), 4.1(1H, m), 3.9(1H, m),
3.0(1H, m), 2.9-2.7 (2H, m), 2.7(3H, s), 1.3(2H, m),
0.95(2H, m) DMSO-d.sub.6
539 17 44
52
##STR105## 8.8(1H, s), 8.6(2H, m), 7.9(1H, d), 7.8(1H, d), 7.4(1H,
q), 5.3 (2H, s), 4.6(2H, s), 4.3(1H, m), 4.1(1H, m),
3.9(1H, m), 3.0(1H, m), 2.9-2.7(2H,m), 2.7(3H, s),
1.3(2H,m), 0.95(2H, m)
DMSO-d.sub.6
496 17 30
53
##STR106## 8.8(1H, s), 7.8(1H, d), 7.6(2H, m), 6.5(1H, m), 5.1(2H,
m), 4.6 (2H, s), 4.3(1H, m), 4.1(1H, m), 3.9(1H, m),
3.0(1H, m), 2.9-2.7 (2H, m), 2.7(3H, s), 1.3(2H, m),
0.95(2H, m) DMSO-d.sub.6
485 17 29
54
##STR107## 8.8(1H, s), 7.8(1H, d), 7.2(3H, m), 6.8(1H, s), 4.6(2H,
s), 4.3 (1H, m), 4.1(1H, m), 3.9(1H, m), 3.0(1H, m),
2.9-2.7(2H, m), 2.7 (3H, s), 1.3(2H, m), 0.95(2H,
DMSO-d.sub.6
571 20 27
55
##STR108## 8.8(1H, s), 8.3(1H, m), 8.0(1H, m), 7.8(1H, d), 7.5(1H,
m), 5.7 (2H, s), 4.6(2H, s), 4.3(1H, m), 4.1(1H, m),
3.9(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 2.7(3H, s),
1.3(2H, m), 0.95(2H, m)
DMSO-d.sub.6
570 17 42
__________________________________________________________________________
TABLE 13
__________________________________________________________________________
Examples 57 to 66
##STR110##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
57
##STR111## 8.4(1H, s), 7.4(2H, bs), 7.2 (2H, d), 7.0(2H, d), 5.1(2H,
s), 4.6(2H, m), 4.2(1H, m), 3.9(1H, m), 3.8(3H, s),
3.7(1H, m), 3.0 (1H, m), 2.8-2.6(2H, m), 1.1 (4H,
DMSO-d.sub.6
528 10 59
58
##STR112## 8.4(1H, s), 7.5(2H, d), 7.4(2H, bs), 7.3(2H, d), 5.2(2H,
s), 4.6 (2H, m), 4.2(1H, m), 3.9(1H, m), 3.7(1H, m),
3.0(1H, m), 2.8-2.6 (2H, m), 1.4(9H, s), 1.1(4H,
DMSO-d.sub.6
554 17 67
59
##STR113## 8.4(1H, s), 7.4(4H, m), 7.1(2H, m), 5.1(2H, s), 4.6(2H,
m), 4.2 (1H, m), 3.9(1H, m), 3.7(1H, m), 3.0(1H, m),
2.8-2.6(2H, m), 1.1 (4H, s)
DMSO-d.sub.6
516 17 55
60
##STR114## 8.4(1H, s), 8.2(2H, d), 7.6(2H, d), 7.4(2H, bs), 5.3(2H,
s), 4.6 (2H, m), 4.2(1H, m), 3.9(1H, m), 3.7(1H, m),
3.0(1H, m), 2.8-2.6 (2H, m), 1.1(4H, s)
DMSO-d.sub.6
543 17 56
61
##STR115## 8.4(1H, s), 7.9-7.4(6H, m), 5.3 (2H, s), 4.6(2H, m),
4.2(1H, m), 3.9(1H, m), 3.7(1H, m), 3.0(1H, m),
2.8-2.6(2H, m), 1.1(4H, s)
DMSO-d.sub.6
523 18 62
62
##STR116## 8.4(1H, s), 7.3(2H, bs), 7.0 (3H, m), 6.2(2H, s), 5.2(2H,
s), 4.6(2H, m), 4.2(1H, m), 3.9(1H, m), 3.7(1H, m),
3.0(1H, m), 2.8- 2.6(2H, m), 1.1(4H, s)
DMSO-d.sub.6
542 18 65
63
##STR117## 8.5(3H, m,), 7.6(1H, d), 7.4(1H, q), 7.3(2H, bs), 5.3(2H,
s), 4.6 (2H, m), 4.2(1H, m), 3.9(1H, m), 3.7(1H, m),
3.0(1H, m), 2.8-2.6 (2H, m), 1.1(4H, s)
DMSO-d.sub.6
499 17 52
64
##STR118## 8.4(1H, s), 7.5-7.4(4H, m), 6.5 (1H, m), 5.0(2H, m),
4.6(2H, m), 4.2(1H, m), 3.9(1H, m), 3.7(1H, m), 3.0(1H,
m), 2.8-2.6(2H, m), 1.1(4H, s)
DMSO-d.sub.6
488 18 49
65
##STR119## 8.4(1H, s), 7.4(2H, bs), 7.1 (3H, m), 6.7(1H, s), 4.6(2H,
m), 4.2(1H, m), 3.9(1H, m), 3.7(1H, m), 3.0(1H, m),
2.8-2.6(2H), 1.1(4H, s)
DMSO-d.sub.6
574 18 43
66
##STR120## 8.4(1H, s), 8.2(1H, m), 7.9(1H, m), 7.4(3H, m), 5.6(2H,
s), 4.6 (2H, m), 4.2(1H, m), 3.9(1H, m), 3.7(1H, m),
3.0(1H, m), 2.8-2.6 (2H, m), 1.1(4H, s)
DMSO-d.sub.6
573 17 65
__________________________________________________________________________
TABLE 14
__________________________________________________________________________
Examples 68 to 77
##STR122##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(min)
(%)
__________________________________________________________________________
68
##STR123## 8.9(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(3H,
m), 7.1 (2H, d), 5.2(2H, s), 4.3(2H, s), 4.0(1H, m),
3.9(1H, m), 3.8(3H, s), 3.0(1H, m), 2.8-2.6(2H,
DMSO-d.sub.6
568 20 78
69
##STR124## 8.9(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(2H, m), 7.3(2H,
m), 5.2 (2H, s), 4.3(2H, s), 3.9(1H, m), 3.0(1H, m),
2.8-2.6(2H, m), 1.5 (9H, s)
DMSO-d.sub.6
594 10 80
70
##STR125## 8.9(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.4(2H,
m), 7.3 (1H, dd), 7.1(2H, m), 5.1(2H, s), 4.3(2H, s),
4.0(1H, m), 3.9 (1H, m), 3.0(1H, m), 2.8-2.6 (2H,
DMSO-d.sub.6
556 15 81
71
##STR126## 8.9(1H, s), 8.3(2H, d), 8.1(1H, d), 7.8(1H, m), 7.7(2H,
d), 7.6 (1H, dd), 7.3(1H, m), 5.3(2H, s), 4.3(2H, s),
4.0(1H, m, 3.9 (1H, m), 3.0(1H, m), 2.8-2.6 (2H,
DMSO-d.sub.6
583 15 75
72
##STR127## 8.8(1H, s), 8.1(1H, d), 7.9-7.4 (6H, m), 7.3(1H, dd),
5.3(2H, s), 4.3(2H, s), 4.0(1H, m), 3.9 (1H, m), 3.0(1H,
m), 2.8-2.6 (2H, m)
DMSO-d.sub.6
563 15 80
73
##STR128## 8.8(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(1H,
dd), 7.0(3H, m), 6.2(2H, s), 5.1(2H, s), 4.3(2H, s),
4.0(1H, m), 3.9 (1H, m), 3.0(1H, m), 2.8-2.6 (2H,
DMSO-d.sub.6
582 15 87
74
##STR129## 8.8(1H, s), 8.6(1H, s), 8.5(1H, q), 7.8(2H, m), 7.6(1H,
dd), 7.4 (1H, q), 7.3(1H, dd), 5.2(2H, s), 4.3(2H, s),
4.0(1H, m), 3.9 (1H, m), 3.0(1H, m), 2.8-2.6 (2H,
DMSO-d.sub.6
539 15 70
75
##STR130## 8.8(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.5(1H,
d), 7.45(1H, dd), 6.6(1H, m), 5.0 (2H, m), 4.3(2H, s),
4.0(1H, m), 3.9(1H, m), 3.0(1H, m), 2.8-2.6(2H,
DMSO-d.sub.6
528 10 69
76
##STR131## 8.8(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(1H,
dd), 7.1(3H, m), 6.7(1H, s), 4.3(2H, s), 4.0(1H, m),
3.9(1H, m), 3.0 (1H, m), 2.8-2.6(2H, m)
DMSO-d.sub.6
614 20 59
77
##STR132## 8.8(1H, s), 8.2(1H, m), 8.1(1H, d), 8.0(1H, m), 7.8(1H,
d), 7.6 (1H, dd), 7.4(1H, m), 7.3(1H, dd), 5.6(2H, s),
4.3(2H, s), 4.0 (1H, m), 3.9(1H, m), 3.0(1H,
m), 2.8-2.6(2H, m,)
DMSO-d.sub.6
613 10 82
__________________________________________________________________________
TABLE 15
__________________________________________________________________________
Examples 79 to 88
##STR134##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
79
##STR135## 8.8(1H, s), 7.8(1H, d), 7.4(2H, d), 7.1(2H, d), 5.0(2H,
s), 4.5 (2H, q), 4.4(2H, s), 4.2(1H, m), 3.9(1H, m),
3.7(3H, s), 3.1(1H, m), 2.9-2.7(2H, m), 1.45(3H,
DMSO-d.sub.6
501 4 73
80
##STR136## 8.8(1H, s), 7.8(1H, d), 7.4(2H, d), 7.2(2H, d), 5.1(2H,
s), 4.5 (2H, q), 4.4(2H, s), 4.1(1H, m), 3.9(1H, m),
3.1(1H, m), 2.9-2.7 (2H, m), 1.45(3H, t), 1.4(9H,
DMSO-d.sub.6
527 2.5
77
81
##STR137## 8.8(1H, s), 7.8(1H, d), 7.3(2H, m), 7.0(2H, m), 5.0(2H,
s), 4.5 (2H, q), 4.4(2H, s), 4.2(1H, m), 3.9(1H, m),
3.1(1H, m), 2.9-2.7 (2H, m), 1.45(3H, t)
DMSO-d.sub.6
489 3 80
82
##STR138## 8.8(1H, s), 8.3(2H, d), 7.8(1H, d), 7.7(2H, d), 5.3(2H,
s), 4.5 (2H, q), 4.4(2H, s), 4.2(1H, m), 3.9(1H, m),
3.1(1H, m), 2.9-2.7 (2H, m), 1.45(3H, t)
DMSO-d.sub.6
516 3 75
83
##STR139## 8.8(1H, s), 7.9-7.4(5H, m), 5.3 (2H, s), 4.5(2H, q),
4.4(2H, s), 4.2(1H, m), 3.9(1H, m), 3.1(1H, m),
2.9-2.7(2H, m), 1.45(3H, t)
DMSO-d.sub.6
496 3 80
84
##STR140## 8.8(1H, s), 7.8(1H, d), 6.8(3H, m), 6.0(2H, s), 5.0(2H,
s), 4.5 (2H, q), 4.4(2H, s), 4.2(1H, m), 3.9(1H, m),
3.1(1H, m), 2.9-2.7 (2H, m), 1.45(3H, t)
DMSO-d.sub.6
515 4 69
85
##STR141## 8.8(1H, s), 8.6(2H, m), 7.8(2H, m), 7.4(1H, q), 5.3(2H,
s), 4.5 (2H, q), 4.4(2H, s), 4.2(1H, m), 3.9(1H, m),
3.1(1H, m), 2.9-2.7 (2H, m), 1.45(3H, t)
DMSO-d.sub.6
471 2 70
86
##STR142## 8.8(1H, s), 7.8(1H, d), 7.5(2H, m), 6.5(1H, m), 5.0(2H,
m), 4.5 (2H, q), 4.4(2H, s), 4.2(1H, m), 2.9(1H, m),
3.1(1H, m), 2.9-2.7 (2H, m), 1.45(3H, t)
DMSO-d.sub.6
461 2 67
87
##STR143## 8.8(1H, s), 7.8(1H, d), 7.1(3H, m), 6.7(1H, s), 4.5(2H,
q), 4.4 (2H, s), 4.2(1H, m), 3.9(1H, m), 3.1(1H, m),
2.9-2.7(2H, m), 1.45(3H, t)
DMSO-d.sub.6
547 3 63
88
##STR144## 8.8(1H, s), 8.2(1H, m), 7.9(1H, m), 7.8(1H, d), 7.4(1H,
m), 5.6 (2H, s), 4.5(2H, q), 4.4(2H, s), 4.2(1H, m),
3.9(1H, m), 3.1(1H, m), 2.9-2.7(2H, m), 1.5(3H,
DMSO-d.sub.6
546 4 70
__________________________________________________________________________
TABLE 16
__________________________________________________________________________
Examples 97 to 106
##STR153##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(min)
(%)
__________________________________________________________________________
97
##STR154##
8.6(1H, s), 8.0(1H, d), 4.7(1H, m), 4.6(2H, s), 4.2(1H, m),
3.9 (1H, m), 3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H, m),
1.2-1.0(4H, m), 0.9(6H, d)
DMSO-d.sub.6
418 10 73
98
##STR155##
8.6(1H, s), 8.05(1H, d), 4.8 (1H, m), 4.7(2H, s), 4.2(1H, m),
4.0(1H, m), 3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 2.2(2H,
m), 2.1(2H, m), 1.7(1H, m), 1.5(1H, m), 1.2-1.0(4H,
DMSO-d.sub.6
430 10 63
99
##STR156##
8.6(1H, s), 8.0(1H, d), 4.7(1H, m), 4.5(2H, s), 4.2(1H, m),
3.9 (1H, m), 3.7(1H, m), 3.1(1H, m), 2.9-2.8(2H, m), 1.7(4H,
s), 1.6 (2H, m), 1.5(2H, m), 1.2-1.0 (4H, m)
DMSO-d.sub.6
444 50 77
100
##STR157##
8.6(1H, s), 8.0(1H, d), 4.8(1H, m), 4.6(2H, s), 4.2(1H, m),
3.9 (1H, m), 3.8-3.6(5H, m), 3.1 (1H, m), 2.9-2.7(2H, m), 2.3-
.9(2H, m), 1.2-1.0(4H, m)
DMSO-d.sub.6
446 30 61
101
##STR158##
8.65(1H, s), 8.05(1H, d), 4.6 (2H, s), 4.25(1H, m), 3.9(1H,
m), 3.85(2H, dd), 3.75(1H, m), 3.1(1H, m), 3.0-2.8(2H, m),
1.3-1.0(5H, m), 0.5(2H, m), 0.3(2H, m)
DMSO-d.sub.6
430 30 84
102
##STR159##
8.6(1H, s), 8.0(1H, d), 4.6(2H, s), 4.2(1H, m), 3.95(1H, m),
3.8 (2H, d), 3.7(1H, m), 3.05(1H, m), 2.9-2.7(2H, m), 1.9(1H,
m), 1.2-1.0(4H, m), 0.9(6H, d)
DMSO-d.sub.6
432 15 80
103
##STR160##
8.60(1H, s), 8.05(1H, d), 4.74 (2H, s), 4.60(2H, s), 4.21(1H,
m), 3.97(1H, m), 3.75(1H, m), 3.50(1H, s), 3.35(2H, s), 3.08
(1H, m), 2.90-2.70(2H, m), 1.30-1.05(4H, m)
DMSO-d.sub.6
414 90 63
104
##STR161##
8.6(1H, s), 8.0(1H, d), 4.6(2H, s), 4.2(1H, m), 4.1(2H, t),
3.9 (1H, m), 3.7(1H, m), 3.1(1H, m), 2.9-2.7(2H, m), 2.8(1H,
s), 2.5 (2H, t), 1.2-1.0(4H, m)
DMSO-d.sub.6
428 15 65
105
##STR162##
8.6(1H, s), 8.0(1H, d), 4.6(2H, s), 4.2(1H, m), 3.9(1H, m),
3.7 (1H, m), 3.4(2H, s), 3.3(3H, s), 3.0(1H, m), 2.8-2.6(2H,
m), 1.2-1.0(4H, m)
DMSO-d.sub.6
420 20 52
106
##STR163##
8.6(1H, s), 8.05(1H, d), 4.6 (2H, s), 4.3(2H, t), 4.2(1H, m),
3.9(1H, m), 3.8(2H, t), 3.7(1H, m), 3.1(1H, m), 2.9-2.7(2H,
m), 1.2-1.0(4H, m)
DMSO-d.sub.6
438 10 50
__________________________________________________________________________
TABLE 17
__________________________________________________________________________
Examples 107 to 116
##STR164##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
107
##STR165##
8.8(1H, s), 7.8(1H, d), 4.7(1H, m), 4.5(2H, s), 4.1(1H, m),
3.9 (1H, m), 3.8(1H, m), 2.9(1H, m), 2.8-2.7(2H, m), 1.15(4H,
s), 0.9(6H, d) DMSO-d.sub.6
435 2 69
108
##STR166##
8.8(1H, s), 7.8(1H, d), 4.8(1H, m), 4.4(2H, s), 4.1(1H, m),
3.9 (1H, m), 3.8(1H, m), 2.9(1H, m), 2.8-2.7(2H, m), 2.2(2H,
m), 2.1 (2H, m), 1.7(1H, m), 1.5(1H, m), 1.15(4H,
DMSO-d.sub.6
447 2 61
109
##STR167##
8.8(1H, s), 7.8(1H, d), 4.7(1H, m), 4.5(2H, s), 4.1(1H, m),
3.9 (1H, m), 3.8(1H, m), 2.9(1H, m), 2.8-2.7(2H, m), 1.7(4H,
s), 1.6 (2H, m), 1.5(2H, m), 1.15(2H, m), 1.0(2H,
DMSO-d.sub.6
461 2 63
110
##STR168##
8.8(1H, s), 7.8(1H, d), 4.8(1H, m), 4.5(2H, s), 4.1(1H, m),
3.9 (1H, m), 3.8-3.6(4H, m), 3.1 (1H, m), 2.8-2.7(2H, m), 2.3-
.9(2H, m), 1.2-1.0(4H, s)
DMSO-d.sub.6
463 2 54
111
##STR169##
8.8(1H, s), 7.8(1H, d), 4.5 (2H, s), 4.1(1H, m), 3.9(1H, m),
3.8(2H, dd), 3.75(1H, m), 3.1 (1H, m), 2.8-2.7(2H, m), 1.15
(4H, m), 1.05(1H, m), 0.5(2H, m), 0.3(2H, m)
DMSO-d.sub.6
447 2 59
112
##STR170##
8.8(1H, s), 7.8(1H, d), 4.5(2H, s), 4.1(1H, m), 3.9(1H, m),
3.8 (2H, d), 3.75(1H, m), 3.0(1H, m), 2.8-2.7(2H, m), 1.9(1H,
m), 1.2-1.0(4H, m), 0.9(6H, d)
DMSO-d.sub.6
449 2 64
113
##STR171##
8.8(1H, s), 7.8(1H, d), 4.62 (2H, s), 4.3(2H, s), 4.1(1H, m),
3.9(1H, m), 3.8(1H, m), 3.5 (1H, s), 2.9(1H, m), 2.8-2.7 (2H,
m), 1.15(4H, m)
DMSO-d.sub.6
431 4 55
114
##STR172##
8.8(1H, s), 7.8(1H, d), 4.5(2H, s), 4.1(1H, m), 4.0(2H, t),
3.9 (1H, m), 3.8(1H, m), 3.1(1H, m), 2.8-2.7(2H, m), 2.7(1H,
s), 2.5 (2H, t), 1.2(4H, m)
DMSO-d.sub.6
445 2 65
115
##STR173##
8.8(1H, s), 7.8(1H, d), 4.5(2H, s), 4.1(1H, m), 3.9(1H, m),
3.8 (1H, m), 3.3(2H, s), 3.1(3H, s), 3.0(1H, m), 2.8-2.7(2H,
m), 1.15(4H, m)
DMSO-d.sub.6
437 1.5
47
116
##STR174##
8.8(1H, s), 7.8(1H, d), 4.5(2H, s), 4.3(2H, t), 4.1(1H, m),
3.9 (1H, m), 3.8(2H, t), 3.75(1H, m), 3.0(1H, m), 2.8-2.7(2H,
m), 1.15(4H, m)
DMSO-d.sub.6
455 1.5
53
__________________________________________________________________________
TABLE 18
__________________________________________________________________________
Examples 117 to 126
##STR175##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
117
##STR176##
8.8(1H, s), 7.9(1H, d), 4.7(1H, m), 4.4(2H, s), 4.3(1H, m),
3.8 (1H, m), 3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H, m),
1.8-0.9(4H, m), 0.9(6H, d)
DMSO-d.sub.6
451 2.5
68
118
##STR177##
8.8(1H, s), 7.9(1H, d), 4.7(1H, m), 4.4(2H, s), 4.3(1H, m),
3.8 (1H, m), 3.7(1H, m,), 3.0(1H, m), 2.9-2.7(2H, m), 2.2(2H,
m), 2.1(2H, m), 1.7(1H, m), 1.5(1H, m), 1.12-0.9(4H,
DMSO-d.sub.6
463 2 61
119
##STR178##
8.8(1H, s), 7.9(1H, d), 4.7(1H, m), 4.4(2H, s), 4.3(1H, m),
3.8 (1H, m), 3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 1.7(4H,
s), 1.6 (2H, m), 1.5(2H, m), 1.2-0.9 (4H, m)
DMSO-d.sub.6
477 2 55
120
##STR179##
8.8(1H, s), 7.9(1H, d), 4.8(1H, m), 4.4(2H, s), 4.3(1H, m),
3.8- 3.6(6H, m), 3.0(1H, m), 2.9-2.7 (2H, m), 2.3-1.9(2H, m),
1.2- 0.9(4H, m)
DMSO-d.sub.6
479 2.5
49
121
##STR180##
8.8(1H, s), 7.9(1H, d), 4.4 (2H, s), 4.3(1H, m), 3.8-3.7 (4H,
m), 3.0(1H, m), 2.9-2.7 (2H, m), 1.2-0.9(5H, m), 0.5 (2H, m),
0.3(2H, m) DMSO-d.sub.6
463 2 52
122
##STR181##
8.8(1H, s), 7.9(1H, d), 4.4(2H, s), 4.3(1H, m), 3.8-3.7(4H,
m), 3.0(1H, m), 2.9-2.7(2H, m), 1.9(1H, m), 1.2-0.9(4H, m),
0.9(6H, d) DMSO-d.sub.6
465 2 60
123
##STR182##
8.8(1H, s), 7.9(1H, d), 4.61 (2H, s), 4.4(2H, s), 4.3(1H, m),
3.8(1H, m), 3.5(1H, s), 3.0(1H, m), 2.9-2.7(2H,
m), 1.2-0.9(4H, m)
DMSO-d.sub.6
447 2 62
124
##STR183##
8.8(1H, s), 7.9(1H, d), 4.4(2H, s), 4.3(1H, m), 4.1(2H, t),
3.8 (1H, m), 3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 2.8(1H,
s), 2.5 (2H, t), 1.2-0.9(4H, m)
DMSO-d.sub.6
461 2.5
57
125
##STR184##
8.8(1H, s), 7.9(1H, d), 4.4(2H, s), 4.3(1H, m), 3.8(1H, m),
3.7 (1H, m), 3.3(2H, s), 3.1(3H, s), 3.0(1H, m), 2.9-2.7(2H,
m), 1.2-0.9(4H, m)
DMSO-d.sub.6
453 1.5
51
126
##STR185##
8.8(1H, s), 7.9(1H, d), 4.4(2H, s), 4.3(3H, m), 3.8-3.7(4H,
m), 3.0(1H, m), 2.9-2.7(2H, m), 1.2-0.9(4H, m)
DMSO-d.sub.6
471 2 64
__________________________________________________________________________
TABLE 19
__________________________________________________________________________
Examples 127 to 136
##STR186##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
127
##STR187##
8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.6(1H, m), 4.4(2H, s),
3.9 (1H, m), 3.8(1H, m), 3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H,
m), 1.3-1.1(4H, m), 0.9(6H, d)
DMSO-d.sub.6
417 3 55
128
##STR188##
8.6(1H, s), 7.8(1H, d), 7.2 (1H, d), 4.7(1H, m), 4.4(2H, s),
3.9(1H, m), 3.8(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 2.2(2H,
m), 2.1(2H, m), 1.7(1H, m), 1.5(2H, m), 1.3-1.1(4H,
DMSO-d.sub.6
429 3 52
129
##STR189##
8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.7(1H, m), 4.4(2H, s),
3.9 (1H, m), 3.8(1H , m), 3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H,
m), 1.7 (4H, s), 1.6(2H, m), 1.5(2H, m), 1.3-1.1(4H,
DMSO-d.sub.6
443 3 59
130
##STR190##
8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.8(1H, m), 4.4(2H, s),
3.9 (1H, m), 3.8-3.6(6H, m), 3.0 (1H, m), 2.9-2.7(2H, m), 2.3-
.9(2H, m), 1.3-1.1(4H, m)
DMSO-d.sub.6
445 3 45
131
##STR191##
8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.6(1H, m), 4.4(2H, s),
3.9 (1H, m), 3.8-3.7(3H, m), 3.1 (1H, m), 2.9-2.7(2H, m), 1.3-
.1(4H, m), 1.0(1H, m), 0.5(2H, m), 0.3(2H, m)
DMSO-d.sub.6
429 3 57
132
##STR192##
8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.4(2H, s), 3.9(1H, m),
3.8 (3H, m), 3.7(1H, m), 3.1(1H, m), 2.9-2.7(2H, m), 1.9(1H,
m), 1.3-1.1(4H, m), 0.9(6H, d)
DMSO-d.sub.6
431 3 76
133
##STR193##
8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.6(2H, s), 4.4(2H, s),
3.9 (1H, m), 3.8(1H, m), 3.7(1H, m), 3.5(1H, s), 3.0(1H, m),
2.9- 2.7(2H, m), 1.3-1.1(4H, m)
DMSO-d.sub.6
413 3 49
134
##STR194##
8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.4(2H, s), 4.1(2H, t),
3.9 (1H, m), 3.8(1H, m), 3.7(1H, m), 3.1(1H, m), 2.9-2.7(2H,
m), 2.8(1H, s), 2.5(2H, t), 1.3- 1.1(4H, m)
DMSO-d.sub.6
427 3 59
135
##STR195##
8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.4(2H, s), 4.1(2H, t),
3.9 (1H, m), 3.8(1H, m), 3.7(1H, m), 3.3(2H, s), 3.2(3H, s),
3.0(1H, m), 2.9-2.7(2H, m), 1.3-1.1 (4H, m)
DMSO-d.sub.6
419 1.5
47
136
##STR196##
8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.4(2H, s), 4.3(2H, t),
3.9 (1H, m), 3.8(3H, m), 3.7(1H, m), 3.0(1H, m), 2.9-2.7(2H,
m), 1.3-1.1(4H, m)
DMSO-d.sub.6
437 2 53
__________________________________________________________________________
TABLE 20
__________________________________________________________________________
Examples 137 to 146
##STR197##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
137
##STR198##
8.8(1H, s), 7.8(1H, d), 4.7(1H, m), 4.5(2H, s), 4.3(1H, m),
4.1 (1H, m), 3.9(1H, m), 3.0(1H, m), 2.8-2.7(2H, m), 2.65(3H,
s), 1.3(2H, m), 1.0(2H, m), 0.9 (6H, d)
DMSO-d.sub.6
447 9 57
138
##STR199##
8.8(1H, s), 7.8(1H, d), 4.8(1H, m), 4.7(2H, s), 4.3(1H, m),
4.2 (1H, m), 3.9(1H, m), 3.0(1H, m), 2.9-2.7(2H, m), 2.7(3H,
s), 2.2 (2H, m), 2.1(2H, m), 1.6(1H, m), 1.5(1H, m), 1.3(2H,
m), 0.95 (2H, m)
DMSO-d.sub.6
459 12 65
139
##STR200##
8.8(1H, s), 7.8(1H, d), 4.7(1H, m), 4.5(2H, s), 4.3(1H, m),
4.2 (1H, m), 3.9(1H, m), 3.1(1H, m), 2.9-2.8(2H, m), 2.7(3H,
s), 1.7 (4H, s), 1.6(2H, m), 1.5(2H, m), 1.3(2H, m), 0.9(2H,
m) DMSO-d.sub.6
473 12 63
140
##STR201##
8.8(1H, s), 7.8(1H, d), 4.8(1H, m), 4.6(2H, s), 4.3(1H, m),
4.2 (1H, m), 4.0(1H, m), 3.8-3.6 (4H, m), 3.1(1H, m), 2.9-2.7
(2H, m), 2.7(3H, s), 2.3-1.9 (2H, m), 1.3(2H, m), 0.9(2H,
DMSO-d.sub.6
475 12 42
141
##STR202##
8.8(1H, s), 7.8(1H, d), 4.6 (2H, s), 4.3(1H, m), 3.9(1H, m),
3.85(2H, dd), 3.1(1H, m), 3.0- 2.8(2H, m), 2.7(3H, s), 1.3(2H,
), 1.1(1H, m), 0.9(2H, m), 0.5(2H, m), 0.3(2H,
DMSO-d.sub.6
459 12 63
142
##STR203##
8.8(1H, s), 7.8(1H, d), 4.6(2H, s), 4.3(1H, m), 4.2(1H, m),
3.95 (1H, m), 3.8(2H, d), 3.05(1H, m), 2.9-2.7(2H, m), 2.7(3H,
s), 1.9(1H, m), 1.3(2H, m), 1.0(2H, m), 0.9(6H,
DMSO-d.sub.6
461 12 68
143
##STR204##
8.8(1H, s), 7.8(1H, d), 4.62 (2H, s), 4.60(2H, s), 4.3(1H, m),
4.1(1H, m), 3.9(1H, m), 3.5 (1H, s), 3.0(1H, m), 2.7(3H, s),
2.9-2.7(2H, m), 1.3(2H, m), 1.0(2H, m)
DMSO-d.sub.6
443 12 30
144
##STR205##
8.8(1H, s), 7.8(1H, d), 4.6(2H, s), 4.3(1H, m), 4.2(1H, m),
4.15(2H, t), 3.1(1H, m), 2.9- 2.7(2H, m), 2.8(1H, s), 2.7(3H,
s), 2.5(3H, t), 1.3(2H, m), 0.9(2H, m)
DMSO-d.sub.6
457 12 52
145
##STR206##
8.8(1H, s), 7.8(1H, d), 4.6(2H, s), 4.3(1H, m), 4.15(1H, m),
3.9 (1H, m), 3.3(2H, s), 3.1(3H, s), 2.9(1H, m), 2.8-2.6(2H,
m), 2.7(3H, s), 1.3(2H, m), 0.9(2H, m)
DMSO-d.sub.6
449 8 39
146
##STR207##
8.8(1H, s), 7.8(1H, d), 4.6(2H, s), 4.3(2H, t), 4.25(1H, m),
4.2 (1H, m), 3.9(1H, m), 3.8(2H, t), 2.9-2.7(2H, m), 2.7(3H,
s), 1.3 (2H, m), 1.0(2H, m)
DMSO-d.sub.6
467 12 57
__________________________________________________________________________
TABE 21
__________________________________________________________________________
Examples 147 to 156
##STR208##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
147
##STR209##
8.4(1H, s), 7.7(2H, br), 4.5 (1H, m), 4.3(2H, s), 4.0-3.8 (3H,
m), 3.2(1H, m), 2.8-2.6 (2H, m), 1.1(4H, s), 0.9 (6H,
DMSO-d.sub.6
450 5 73
148
##STR210##
8.3(1H, s), 7.3(2H, br), 4.8 (1H, m), 4.3(2H, s), 4.0-3.8 (3H,
m), 2.8-2.6(2H, m), 2.2 (2H, m), 2.1(2H, m), 1.6(1H, m),
1.5(1H, m), 1.1(4H, m)
DMSO-d.sub.6
462 8 64
149
##STR211##
8.4(1H, s), 7.4(2H, br), 4.7 (1H, m), 4.5(2H, s), 4.2(1H, m),
3.9(1H, m), 3.7(1H, m), 3.0(1H, m), 2.8-2.6(2H, m), 1.7(4H,
s), 1.6(2H, m), 1.5(2H, m), 1.1 (4H, m)
DMSO-d.sub.6
476 8 61
150
##STR212##
8.4(1H, s), 7.4(2H, br), 4.8 (1H, m), 4.6(2H, s), 4.2(1H, m),
4.0(1H, m), 3.8-3.6(4H, m), 3.0(1H, m), 2.8-2.6(2H, m),
2.3-1.9(2H, m), 1.2-0.9(4H, m)
DMSO-d.sub.6
478 12 54
151
##STR213##
8.4(1H, s), 7.5(2H, br), 4.6 (2H, s), 3.9(1H, m), 3.8(2H, dd),
3.0(1H, m), 2.9-2.8(2H, m), 1.0(1H, m), 0.5(2H, m), 0.3(2H,
DMSO-d.sub.6
462 5 82
152
##STR214##
8.4(1H, s), 7.5(2H, br), 4.5 (2H, s), 3.9(1H, m), 3.8(2H, dd),
3.1(1H, m), 2.9-2.7(2H, m), 1.9(1H, m), 1.2-1.1(4H, m),
0.9(6H, d) DMSO-d.sub.6
464 6 75
153
##STR215##
8.4(1H, s), 7.4(2H, br), 4.6 (2H, s), 4.59(2H, m), 4.2(1H, m),
3.9(1H, m), 3.7(1H, m), 3.5 (1H, s), 3.0(1H, m), 2.8-2.6 (2H,
m), 1.1(4H, s) DMSO-d.sub.6
446 4 50
154
##STR216##
8.4(1H, s), 7.5(2H, br), 4.4 (2H, s), 4.1(1H, m), 4.0(2H, t),
3.9(1H, m), 3.8(1H, m), 3.1(1H, m), 2.8-2.7(2H, m), 2.8(1H,
s), 2.5(2H, t), 1.2-0.9(4H, m)
DMSO-d.sub.6
460 5 70
155
##STR217##
8.4(1H, s), 7.4(2H, br), 4.4 (2H, s), 4.3(2H, t), 4.1(1H, m),
3.9(1H, m), 3.7(2H, t), 3.6(1H, m), 3.3(2H, s), 3.0(3H, s),
2.9 (1H, m), 2.8-2.6(2H, m), 1.3-0.9(4H, m)
DMSO-d.sub.6
452 3 60
156
##STR218##
8.4(1H, s), 7.4(2H, br), 4.4 (2H, s), 4.3(2H, t), 4.0(2H, m),
3.9(1H, m), 3.8(2H, t), 3.7(1H, m), 3.2(1H, m), 2.9-2.7(2H,
m), 1.1(4H, s) DMSO-d.sub.6
470 5 72
__________________________________________________________________________
TABLE 22
__________________________________________________________________________
Examples 157 to 166
##STR219##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(min)
(%)
__________________________________________________________________________
157
##STR220##
8.8(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(1H, dd),
4.6(1H, m), 4.3(2H, s), 4.0(1H, m), 3.9(1H, m), 3.0(1H, m),
2.8-2.6(2H, m), 0.9(6H, d)
DMSO-d.sub.6
490 15 64
158
##STR221##
8.8(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(1H, dd),
4.7(1H, m), 4.4(2H, s), 4.0(1H, m), 3.9(1H, m), 3.0(1H, m),
2.8- 2.6(2H, m), 2.2(2H, m), 2.1(2H, m), 1.7(1H, m), 1.5(1H,
m) DMSO-d.sub.6
502 20 61
159
##STR222##
8.8(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(1H, dd),
4.7(1H, m), 4.4(2H, s), 4.0(1H, m), 3.9(1H, m), 3.0(1H, m),
2.8- 2.6(2H, m), 2.2(2H, m), 2.1(2H, m), 1.7(1H, m), 1.5(1H,
m) DMSO-d.sub.6
516 35 70
160
##STR223##
8.8(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(1H, dd),
4.8(1H, m), 4.4(2H, s), 4.0(1H, m), 3.9(1H, m), 3.8-3.6(4H,
m), 3.0(1H, m), 2.9-2.6(2H, m), 2.3-1.9(2H, m)
DMSO-d.sub.6
518 35 55
161
##STR224##
8.8(1H, s), 8.1(1H, d), 7.8 (1H, dd), 7.6(1H, dd), 7.3(1H,
dd), 4.6(2H, s), 4.2(1H, m), 3.9(1H, m), 3.8(2H, dd), 3.0 (1H,
m), 2.8-2.6(2H, m), 1.1 (1H, m), 0.5(2H, m), 0.3(2H,
DMSO-d.sub.6
502 30 65
162
##STR225##
8.8(1H, s), 8.1(1H, d), 7.8(1H, dd), 7.6(1H, dd), 7.3(1H, dd),
.6(2H, s), 4.0(1H, m), 3.9(1H, m), 3.8(2H, d), 3.0(1H, m),
2.8-2.6(2H, m), 1.9(1H, m), 0.9(6H, d)
DMSO-d.sub.6
504 20 70
163
##STR226##
8.79(1H, s), 8.01(1H, d), 7.8 (1H, m), 7.6(1H, dd), 7.3(1H,
dd), 4.73(2H, s), 4.61(2H, s), 4.21(1H, m), 3.75(1H, m), 3.50
(1H, s), 3.35(2H, s), 3.08(1H, m), 2.90-2.70(2H,
DMSO-d.sub.6
486 60 52
164
##STR227##
8.8(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(1H, dd),
4.6(2H, s), 4.1(1H, m), 4.0(2H, t), 3.9(1H, m), 3.0(1H, m),
2.8-2.6(2H, m), 2.7(1H, s), 2.5(2H, t)
DMSO-d.sub.6
500 25 53
165
##STR228##
8.8(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(1H, dd),
4.6(2H, s), 4.1(1H, m), 3.9(1H, m), 3.3(2H, s), 3.1(3H, s),
3.0 (1H, m), 2.8-2.6(2H, m)
DMSO-d.sub.6
492 30 47
166
##STR229##
8.8(1H, s), 8.1(1H, d), 7.8(1H, m), 7.6(1H, dd), 7.3(1H, m),
4.6 (2H, s), 4.3(2H, t), 4.1(1H, m), 3.9(1H, m), 3.8(2H, t),
3.1(1H, m), 2.8-2.6(2H, m)
DMSO-d.sub.6
510 15 51
__________________________________________________________________________
TABLE 23
__________________________________________________________________________
Examples 167 to 176
##STR230##
FAB,
Reac.
Examp. NMR MS time
Yield
No. R .sup.1 H NMR, δ (ppm)
solv.
(M + 1)
(hr)
(%)
__________________________________________________________________________
167
##STR231##
8.8(1H, s), 7.8(1H, d), 4.6(1H, m), 4.5(2H, q), 4.4(2H, s),
4.2 (1H, m), 3.9(1H, m), 3.1(1H, m), 2.9-2.7(2H, m), 1.45(3H,
t), 0.9(6H, d) DMSO-d.sub.6
423 4.5
82
168
##STR232##
8.8(1H, s), 7.8(1H, d), 4.7(1H, m), 4.5(2H, q), 4.4(2H, s),
4.2 (1H, m), 4.1(1H, m), 3.1(1H, m), 2.9-2.7(2H, m), 2.2(2H,
m), 2.1 (2H, m), 1.7(1H, m), 1.6(1H, m), 1.45(3H,
DMSO-d.sub.6
435 5 73
169
##STR233##
8.8(1H, s), 7.8(1H, d), 4.75 (1H, m), 4.6(2H, s), 4.5(2H, q),
4.2(1H, m), 3.9(1H, m), 3.0-2.7 (2H, m), 1.8(4H, s), 1.65(2H,
s), 1.5(2H, s), 1.4(3H, t)
DMSO-d.sub.6
449 5 77
170
##STR234##
8.7(1H, s), 7.8(1H, d), 4.8(1H, m), 4.55(2H, s), 4.5(2H, dd),
4.15(1H, m), 3.85(1H, m), 3.7 (2H, m), 3.1(1H, m), 2.9-2.7
(2H, m), 2.1-1.9(2H, m), 1.5 (3H, t)
DMSO-d.sub.6
451 6 71
171
##STR235##
8.8(1H, s), 7.8(1H, d), 4.6 (2H, s), 4.45(2H, m), 4.25(1H, m),
3.9(2H, dd), 3.7(1H, m), 3.1(1H, m), 1.45(3H, t), 0.5 (2H, m),
0.25(2H, m) DMSO-d.sub.6
435 5 84
172
##STR236##
8.8(1H, s), 7.8(1H, d), 4.6(2H, s), 4.5(2H, q), 4.2(1H, m),
3.9 (1H, m), 3.85(2H, dd), 3.1(1H, m), 2.9-2.7(2H, m), 1.9(1H,
m), 0.9(6H, d) DMSO-d.sub.6
437 4 70
173
##STR237##
8.8(1H, s), 7.8(1H, d), 4.62 (2H, s), 4.5(2H, q), 4.4(2H, s),
4.2(1H, m), 3.9(1H, m), 3.5(1H, s), 3.1(1H, m), 2.9-2.7(2H,
m), 1.45(3H, t)
DMSO-d.sub.6
419 3 50
174
##STR238##
8.8(1H, s), 7.8(1H, d), 4.5(2H, dd), 4.2(1H, m), 4.15(2H, t),
3.9(1H, m), 3.1(1H, m), 2.9- 2.7(2H, m), 2.8(1H, s), 2.5(2H,
t), 1.5(3H, t) DMSO-d.sub.6
433 4.5
72
175
##STR239##
8.8(1H, s), 7.8(1H, d), 4.6(2H, s), 4.5(2H, dd), 4.15(1H, m),
3.9(1H, m), 3.3(2H, s), 3.1(3H, s), 2.9(1H, m), 2.8(1H, m),
2.6 (1H, m), 1.5(3H, t)
DMSO-d.sub.6
425 2 39
176
##STR240##
8.8(1H, s), 7.8(1H, d), 4.6(2H, s), 4.5(2H, dd), 4.3(2H, t),
4.2 (1H, m), 3.9(1H, m), 3.8(2H, t), 2.9-2.7(2H, m), 1.5(3H,
t) DMSO-d.sub.6
443 2 57
__________________________________________________________________________
TABLE 24
__________________________________________________________________________
Examples 183 to 202
##STR247##
FAB MS
Reac.
Ex. .sup.1 H NMR (DMSO-d.sub.6)
(POS)
Time
Yield
No.
Q R.sub.1 R.sub.2
δ (ppm) M + H!
(hr)
(%)
__________________________________________________________________________
183
CF
##STR248##
H 8.8(1H, s), 7.9(1H, d), 4.35(1H, m), 3.8(2H, m),
3.7(2H, m), 3.4 (1H, m), 3.0(2H, m), 1.2-1.0 (4H,
393 2.5
41
184
CF
##STR249##
Et 8.8(1H, s), 7.9(1H, d), 4.4(1H, m), 4.2(2H, q),
4.1-3.9(2H, m), 3.4(2H, m), 2.8(2H, m), 1.4(3H, t),
1.25-1.0(4H, m) 421 2 38
185
CF
##STR250##
Ph 8.8(1H, s), 7.9(1H, d), 7.3-7.1 (5H, m), 4.3(1H, m),
3.9-3.7(3H, m), 3.4(2H, m), 2.8(2H, m), 1.2 (2H, d),
1.05(2H, s) 469 4 29
186
CF
##STR251##
tBu
8.8(1H, s), 7.9(1H, d), 4.35(1H, d), 4.1-3.9(3H, m),
3.4(2H, m), 2.9-2.7(2H, m), 1.35(9H, s), 1.2-0.95(4H,
m) 449 2 35
187
CCl
##STR252##
H 8.9(1H, s), 7.9(1H, d), 4.4(1H, m), 3.8(2H, m), 3.7(2H,
m), 3.4 (1H, m), 2.9(2H, m), 1.25(2H, m), 1.1(2H,
409 1.5
39
188
CCl
##STR253##
Et 8.9(1H, s), 7.9(1H, d), 4.35 (1H, m), 4.2(2H, q),
3.95-3.75 (3H, m), 3.7(2H, m), 3.4(2H, m), 2.85-2.7(2H,
m), 1.4(3H, t), 1.3-1.15(4H, m)
437 1.5
37
189
CCl
##STR254##
Ph 8.9(1H, s), 7.9(1H, d), 7.3-7.1 (5H, m), 4.35(1H, m),
4.1-3.9 (3H, m), 3.65(2H, m), 3.35(2H, m), 2.8-2.7(2H,
m), 1.15(2H, d), 0.95(2H, s)
485 4.5
25
190
CCl
##STR255##
tBu
8.9(1H, s), 7.85(1H, d), 4.3(1H, m),3.95-3.8(3H, m),
3.7(2H, m), 3.4(2H, m), 2.8(2H, m), 1.3(9H, s),
1.2-1.0(4H, m) 465 3 51
191
CH
##STR256##
H 8.6(1H, s), 7.85(1H, d), 7.2(1H, d), 4.4(1H, m),
3.9(2H, m), 3.8- 3.65(3H, m), 2.9-2.7(2H, m), 1.3 (2H,
d), 1.1(2H, s) 375 2.2
42
192
CH
##STR257##
Et 8.6(1H, s), 7.8(1H, d), 7.2(1H, d), 4.4(1H, m),
4.25(2H, q), 3.9- 3.7(3H, m), 3.5(2H, m), 2.9-2.7 (2H,
m), 1.3(3H, t), 1.25-0.95 (4H, m)
403 1.5
40
193
CH
##STR258##
Ph 8.6(1H, s), 7.8(1H, d), 7.5-7.2 (5H, m, 1H, d),
4.35(1H, m), 4.0- 3.8(3H, m), 3.5(2H, m), 2.85-2.7 (2H,
m), 1.3(2H, d), 1.15(2H, s)
451 4.5
31
194
CH
##STR259##
tBu
8.6(1H, s), 7.75(1H, d), 7.2(1H, d), 4.35(1H, m),
4.0-3.8(3H, m), 3.5(2H, m), 2.9-2.7(2H, m), 1.4 (9H,
s), 1.2-1.05(4H, m)
431 3 43
195
N
##STR260##
H 8.6(1H, s), 8.1(1H, d), 4.5(2H, s), 4.3(1H, m), 3.8(1H,
m), 3.65 (1H, m), 3.35(1H, m), 3.0-2.9 (2H, m),
1.2-1.0(4H, m) 376 1 61
196
N
##STR261##
Et 8.6(1H, s), 8.05(1H, d), 4.55 (2H, s), 4.3(1H, m),
4.25(2H, q), 3.8(1H, m), 3.7(1H, m), 3.4 (1H, m),
3.0-2.85(2H, m), 1.35 (3H, t), 1.2-0.95(4H,
404 1 57
197
N
##STR262##
Ph 8.6(1H, s), 8.1(1H, d), 7.7-7.3 (5H, m), 4.6(2H, s),
4.35(1H, m), 3.9(1H, m), 3.75(1H, m), 3.4(1H, m),
3.05-2.8(3H, m), 1.25(2H, d), 1.05(2H,
452 1 40
198
N
##STR263##
tBu
8.6(1H, s), 8.05(1H, d), 4.55 (2H, s), 4.35(1H, m),
3.95(1H, m), 3.7(1H, m), 3.35(1H, m), 3.0- 2.85(2H, m),
1.35(9H, s), 1.15 (2H, d), 1.0(2H, s)
432 1.5
54
199
N
##STR264##
H 8.85(1H, s), 8.1(1H, d), 7.75 (1H, m), 7.6(1H, dd),
7.35(1H, dd), 4.3(1H, m), 3.8(3H, m), 3.6 (1H, m),
3.0(1H, m), 2.7(2H, m)
448 1 33
200
N
##STR265##
Et 8.85(1H, s), 8.05(1H, d), 7.75 (1H, m), 7.6(1H, dd),
7.35(1H, dd), 4.3(1H, m), 4.25(2H, q), 3.75(3H, m),
3.6(2H, m), 2.95 (2H, m), 2.7-2.6(2H, m), 1.4 (3H,
476 1 37
201
N
##STR266##
Ph 8.85(1H, s), 8.1(1H, d), 7.75 (1H, m), 7.6(1H, dd),
7.55-7.35 (5H, m, 1H, dd), 4.35(1H, m), 3.75 (3H, m),
3.65(2H, m), 3.0(2H, m), 2.85(2H, m)
524 1.5
29
202
N
##STR267##
tBu
8.85(1H, s), 8.05(1H, d), 7.75 (1H, m), 7.55(1H, dd),
7.3(1H, dd), 4.3(1H, m), 3.8(3H, m), 3.55 (2H, m),
2.9(2H, m), 2.7-2.65 (2H, m), 1.3(9H,
504 0.5
41
__________________________________________________________________________
TABLE 25
______________________________________
Minimum Inhibitory Concentration of the test compounds
(μg/ml)
______________________________________
Examples
Test Strains 1 12 34 56 89
______________________________________
Staphylococcus aureus
≦0.008
≦0.008
≦0.008
≦0.008
≦0.008
6538p
Staphylococcus aureus
≦0.008
≦0.008
≦0.008
≦0.008
≦0.008
giorgio
Staphylococcus aureus
≦0.008
≦0.008
≦0.008
≦0.008
≦0.008
77
Staphylococcus aureus
2 1 4 2 1
241
Staphylococcus
≦0.008
≦0.008
≦0.008
≦0.008
≦0.008
epidermidis 887E
Staphylococcus
2 0.5 2 2 0.5
epidermidis 178
Streptococcus faecalis
0.031 0.031 0.13 0.016 0.063
29212
Bacillus subtilis 6633
≦0.008
≦0.008
≦0.008
≦0.008
≦0.008
Micrococcus luteus 9341
0.063 0.13 0.13 0.063 0.25
Escherichia coli 10536
≦0.008
≦0.008
0.016 ≦0.008
0.016
Escherichia coli 3190Y
≦0.008
0.016 ≦0.008
≦0.008
0.016
Escherichia coli 851E
0.016 0.063 0.13 ≦0.008
0.063
Escherichia coli
0.25 0.5 1 0.5 0.25
TEM3 3455E
Escherichia coli
0.063 0.25 0.5 0.25 0.13
TEM5 3739E
Escherichia coli
0.063 0.25 0.13 0.063 0.063
TEM9 2639E
Pseudomonas aeruginosa
1 2 0.5 2 2
1912E
Pseudomonas aeruginosa
2 0.5 2 2 2
10145
Acinetobacter
≦0.008
0.016 0.031 ≦0.008
0.031
calcoaceticus 15473
Citrobacter diversus
0.063 0.13 0.25 0.016 0.13
2046E
Enterobacter cloacae
0.031 0.13 0.25 0.031 0.13
1194E
Enterobacter cloacae
≦0.008
0.063 0.063 ≦0.008
0.016
P99
Klebsiella aerogenes
0.25 1 0.5 0.5 0.5
1976E
Klebsiella aerogenes
0.063 0.13 0.031 0.016 0.25
1082E
Salmonella typimurium
0.13 0.25 0.063 0.031 0.13
14028
______________________________________
Examples
Test Strains 97 102 103 104 177
______________________________________
Staphylococcus aureus
≦0.008
0.016 ≦0.008
≦0.008
≦0.008
6538p
Staphylococcus aureus
≦0.008
≦0.008
≦0.008
≦0.008
≦0.008
giorgio
Staphylococcus aureus
0.016 0.016 ≦0.008
≦0.008
0.016
77
Staphylococcus aureus
2 4 4 8 0.5
241
Staphylococcus
≦0.008
≦0.008
≦0.008
0.016 ≦0.008
epidermidis 887E
Staphylococcus
1 1 4 4 1
epidermidis 178
Streptococcus faecalis
0.063 0.063 0.031 0.031 0.031
29212
Bacillus subtilis 6633
≦0.008
≦0.008
≦0.008
≦0.008
≦0.008
Micrococcus luteus 9341
0.063 0.063 0.13 0.13 0.063
Escherichia coli 10536
≦0.008
≦0.008
≦0.008
≦0.008
≦0.008
Escherichia coli 3190Y
≦0.008
≦0.008
≦0.008
≦0.008
≦0.008
Escherichia coli 851E
0.031 0.063 ≦0.008
≦0.008
0.031
Escherichia coli
0.13 0.5 0.13 0.25 0.25
TEM3 3455E
Escherichia coli
0.063 0.25 0.063 0.13 0.13
TEM5 3739E
Escherichia coli
0.031 0.063 0.031 0.031 0.063
TEM9 2639E
Pseudomonas aeruginosa
1 2 0.5 1 0.5
1912E
Pseudomonas aeruginosa
1 2 0.5 1 0.5
10145
Acinetobacter
0.016 0.063 0.031 ≦0.008
0.13
calcoaceticus 15473
Citrobacter diversus
0.063 0.13 0.13 ≦0.008
0.031
2046E
Enterobacter cloacae
0.063 0.25 0.016 ≦0.008
0.063
1194E
Enterobacter cloacae
≦0.008
0.031 ≦0.008
0.016 0.016
P99
Klebsiella aerogenes
0.25 0.5 0.063 0.13 0.13
1976E
Klebsiella aerogenes
0.13 0.25 0.031 0.031 0.063
1082E
Salmonella typimurium
0.13 0.25 0.031 0.031 0.063
14028
______________________________________
Examples
Test Strains 178 179 180 OFLX CFLX
______________________________________
Staphylococcus aureus
0.031 ≦0.008
≦0.008
0.25 0.13
6538p
Staphylococcus aureus
0.016 0.016 ≦0.008
0.25 0.25
giorgio
Staphylococcus aureus
0.031 0.031 ≦0.008
0.25 0.25
77
Staphylococcus aureus
1 2 2 64 64
241
Staphylococcus
0.031 0.016 ≦0.008
0.25 0.13
epidermidis 887E
Staphylococcus
1 2 2 32 128
epidermidis 178
Streptococcus faecalis
0.063 0.031 0.063 2 0.5
29212
Bacillus subtilis 6633
0.016 ≦0.008
≦0.008
0.063 0.031
Micrococcus luteus 9341
0.25 0.13 0.13 2 2
Escherichia coli 10536
0.031 <0.008 ≦0.008
0.031 ≦0.008
Escherichia coli 3190Y
0.016 ≦0.008
≦0.008
0.016 ≦0.008
Escherichia coli 851E
0.063 ≦0.008
≦0.008
0.063 0.016
Escherichia coli
1 0.13 0.25 0.5 0.25
TEM3 3455E
Escherichia coli
0.5 0.063 0.13 0.5 0.13
TEM5 3739E
Escherichia coli
0.25 0.031 0.031 0.063 0.031
TEM9 2639E
Pseudomonas aeruginosa
0.5 0.25 0.25 0.5 0.31
1912E
Pseudomonas aeruginosa
1 0.25 0.25 2 0.25
10145
Acinetobacter
0.13 0.016 0.0634
0.25 0.25
calcoaceticus 15473
Citrobacter diversus
0.13 0.031 0.016 0.063 0.016
2046E
Enterobacter cloacae
0.13 0.031 0.031 0.063 0.031
1194E
Enterobacter cloacae
0.063 0.008 ≦0.008
≦0.008
≦0.008
P99
Klebsiella aerogenes
0.5 0.13 0.13 0.25 0.13
1976E
Klebsiella aerogenes
0.25 0.031 0.016 0.063 ≦0.008
1082E
Salmonella typimurium
0.063 0.063 0.031 0.13 0.031
14028
______________________________________
Note)
OFLX = Ofloxacin
CFLX = Ciprofloxacin
TABLE 26
______________________________________
Pharmacokinetic parameters
T.sub.1/2 C.sub.max T.sub.max
F
Route (hr) (μg/ml)
(hr) (%)
______________________________________
CFLX IV 1.76 ± 0.035 71
PO 1.7 ± 0.108
1.34 ± 0.368
1.13 ± 0.605
EX. 89
IV 2.29 ± 1.13 >100
PO 6.69 ± 2.78
4.89 ± 2.23
2.18 ± 0.77
EX. 177
IV 1.92 ± 0.38 47.23
PO 3.93 ± 1.31
0.37 ± 0.11
0.51 ± 0.33
______________________________________
Note:
CFLX = Ciprofloxacin
IV = Intravenous
PO = Per oral
T.sub.1/2 = Biological half life
C.sub.max = Maximum blood concentration
T.sub.max = Time showing maximum blood concentration after administration
of the test compound
F = Bioavailability
TABLE 27 ______________________________________ Toxicity Test Compound LD.sub.50 value (Example No.) (mg/kg) ______________________________________ 1 >3,000 34 >3,000 ______________________________________
TABLE 28 ______________________________________ Saturated salt solutions inside the desiccator Salt Solution Relative Humidity (%) at 25° C. ______________________________________Potassium Acetate 23Magnesium Chloride 33Potassium Carbonate 43Magnesium Nitrate 52Sodium Nitrite 64Sodium Chloride 75 ______________________________________
TABLE 29
______________________________________
Thermal stability with elapsed time (at 70° C.)
(Unit: %)
Time (week)
Sample Initial 1 2 3 4
______________________________________
Anhydrate 99 -- 97 -- 95
3 hydrate 97 -- -- -- 94
1.5 hydrate
100 97.25 95.80 97.16
96.17
______________________________________
TABLE 30
______________________________________
Water Solubility
Phosphate buffered
Phosphate buffered
Sample solution (pH 7)
solution (pH 2)
______________________________________
Free form 0.007 14.6
Tartarate 6.7 15.4
Sulfurate 11.4 8.9
p-Toluenesulfonate
7.5 6.8
Methanesulfonate
>30 >20
______________________________________
TABLE 31
______________________________________
In vitro Antibacterial activity (Minimum Inhibitory
Concentration: MIC, μg/ml)
Test Strains E-isomer Z-isomer Ciprofloxacin
______________________________________
Staphylococcus aureus 6538p
0.063 ≦0.008
0.13
Staphylococcus aureus giorgio
0.063 ≦0.008
0.13
Staphylococcus aureus 77
0.063 0.031 0.25
Staphylococcus aureus 241
16 4 64
Staphylococcus epidermidis
0.031 ≦0.008
0.063
887E
Staphylococcus epidermidis 178
32 4 128
Streptococcus faecalis 29212
0.25 0.063 1
Bacillus subtilis 6633
0.031 ≦0.008
0.031
Micrococcus luteus 9341
0.5 0.13 2
Escherichia coli 10536
0.031 ≦0.008
0.016
Escherichia coli 3190Y
0.016 ≦0.008
≦0.008
Escherichia coli 851E
0.063 0.016 ≦0.008
Escherichia coli TEM3 3455E
0.5 0.13 0.25
Escherichia coli TEM5 3739E
0.5 0.13 0.13
Escherichia coli TEM9 2639E
0.13 0.031 0.016
Pseudomonas aeruginosa 1912E
1 0.5 0.25
Pseudomonas aeruginosa 10145
2 0.5 0.25
Pseudomonas aeruginosa 6065Y
32 8 4
Acinetobacter calcoaceticus
0.25 0.063 0.25
15473
Citrobacter diversus 2046E
0.13 0.031 0.031
Enterobacter cloacae 1194E
0.13 0.031 0.016
Enterobacter cloacae P99
0.031 ≦0.008
≦0.008
Klebsiella aerogenes 1976E
0.25 0.063 0.13
Klebsiella aerogenes 1082E
0.13 0.031 0.016
Proteus vulgaris 6059
1 0.25 0.031
Seratis marsecence 1826E
0.5 0.25 0.063
Salmonella thypimurium 14028
0.13 0.031 0.031
______________________________________
TABLE 32
______________________________________
In vitro Antibacterial activity (Minimum Inhibitory
Concentration: MIC, μg/ml)
Methanesulfonic
Test Strains acid salt Ciprofloxacin
______________________________________
Staphylococcus aureus 6538p
0.016 0.13
Staphylococcus aureus giorgio
0.016 0.13
Staphylococcus aureus 77
0.031 0.25
Staphylococcus aureus 241
4 128
Staphylococcus epidermidis 887E
0.016 0.013
Staphylococcus epidermidis 178
4 128
Streptococcus faecalis 29212
0.13 0.5
Bacillus subtilis 6633
0.016 0.031
Micrococcus luteus 9341
0.13 2
Escherichia coli 10536
0.008 <0.008
Escherichia coli 3190Y
0.008 <0.008
Escherichia coli 851E
0.016 <0.008
Escherichia coli TEM3 3455E
0.25 0.5
Escherichia coli TEM5 3739E
0.13 0.13
Escherichia coli TEM9 2639E
0.031 0.016
Pseudomonas aeruginosa 1912E
0.25 0.13
Pseudomonas aeruginosa 10145
0.5 0.5
Acinetobacter calcoaceticus 15473
0.031 0.25
Citrobacter diversus 2046E
0.031 0.016
Enterobacter cloacae 1194E
0.031 0.016
Enterobacter cloacae P99
0.016 <0.008
Klebsiella aerogenes 1976E
0.13 0.13
Klebsiella aerogenes 1082E
0.031 0.016
Proteus vulgaris 6059
0.25 0.031
Seratis marsecence 1826E
0.13 0.063
Salmonella thypimurium 14028
0.031 0.031
______________________________________
Claims (16)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/825,992 US5776944A (en) | 1994-06-16 | 1997-04-04 | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
| US09/049,024 US5869670A (en) | 1994-06-16 | 1998-03-27 | 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
| US09/188,063 US5962468A (en) | 1994-06-16 | 1998-11-09 | 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1- cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-1, 8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR94-13604 | 1994-06-16 | ||
| KR1019940013604A KR0131999B1 (en) | 1994-06-16 | 1994-06-16 | Novel quinoline carboxylic acid derivatives having 7-(4-aminomethyl-3-oxime) pyrrolidine substituent and process for preparing thereof novel substituted imidazole derivatives |
| KR1019940039915A KR100222082B1 (en) | 1994-12-30 | 1994-12-30 | Novel quinoline carboxylic acid derivatives with 7-(3-aminomethyl-4-alkyloxime) pyrrolidine substituent and process for preparation thereof |
| KR94-39930 | 1994-12-30 | ||
| KR1019940039930A KR100222083B1 (en) | 1994-12-30 | 1994-12-30 | Novel quinoline carboxylic acid derivatives having (3-aminomethyl-4-benzyloxime)pyrrolidine substituient at 7 position and process for preparation thereof |
| KR94-39915 | 1994-12-30 | ||
| US08/490,978 US5633262A (en) | 1994-06-16 | 1995-06-15 | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof |
| US08/825,992 US5776944A (en) | 1994-06-16 | 1997-04-04 | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/490,978 Continuation-In-Part US5633262A (en) | 1994-06-16 | 1995-06-15 | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/049,024 Division US5869670A (en) | 1994-06-16 | 1998-03-27 | 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5776944A true US5776944A (en) | 1998-07-07 |
Family
ID=46252590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/825,992 Expired - Lifetime US5776944A (en) | 1994-06-16 | 1997-04-04 | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US5776944A (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262071B1 (en) * | 1999-06-29 | 2001-07-17 | Smithkline Beecham Corporation | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
| AU751060B2 (en) * | 1998-09-18 | 2002-08-08 | Lg Life Sciences Limited | Process for the production of a naphthyridine carboxylic acid derivative (methanesulfonate sesquihydrate) |
| US6455540B1 (en) | 1999-06-29 | 2002-09-24 | Smithkline Beecham Corporation | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
| US20040034221A1 (en) * | 2000-10-12 | 2004-02-19 | Anthony Neville J | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| US6703512B1 (en) | 1999-09-03 | 2004-03-09 | Sb Pharmco Puerto Rico Inc. Of The United States Corporation Company | Intermediates for the production of quinolone carboxylic acid derivatives |
| US6723734B2 (en) * | 1997-03-21 | 2004-04-20 | Lg Life Sciences, Ltd. | Salt of naphthyridine carboxylic acid derivative |
| US20040097520A1 (en) * | 1999-07-08 | 2004-05-20 | Smithkline Beecham Corporation | Methods of use of fluoroquinolone compounds against ciprofloxacin-resistant and ciprofloxacin-sensitive pathogenic bacteria |
| US20040180903A1 (en) * | 1999-06-29 | 2004-09-16 | Jacques Dubois | Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria |
| US6803376B1 (en) | 1999-06-29 | 2004-10-12 | Smithkline Beecham Corporation | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
| US20050032813A1 (en) * | 1999-09-14 | 2005-02-10 | Jacques Dubois | Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria |
| US20050043546A1 (en) * | 2001-08-02 | 2005-02-24 | Brechtelsbauer Clemens Michael Helmut | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof |
| US20050148622A1 (en) * | 2002-04-08 | 2005-07-07 | Lg Life Sciences Ltd | Process for preparing acid salts of gemifloxacin |
| US20050176955A1 (en) * | 2002-03-15 | 2005-08-11 | Melissa Egbertson | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors |
| US20050176961A1 (en) * | 1999-09-03 | 2005-08-11 | Sb Pharmco Puerto Rico Inc. | Process for production of naphthyridine-3-carboxylic acid derivatives |
| US20060059919A1 (en) * | 2004-09-07 | 2006-03-23 | Leachman David P | System and method for improving thermal efficiency of dry low emissions combustor assemblies |
| US20070282107A1 (en) * | 2003-03-07 | 2007-12-06 | Lg Life Sciences Ltd. | New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate |
| US20080039488A1 (en) * | 1997-03-21 | 2008-02-14 | Lg Life Sciences, Ltd. | Salt of naphthyridine carboxylic acid derivative |
| USRE45090E1 (en) | 2001-05-15 | 2014-08-26 | Panduit Corp. | Cable tie with wide neck |
| EP2969004A1 (en) | 2013-03-15 | 2016-01-20 | Melinta Therapeutics, Inc. | Methods of treating infections in overweight and obese patients using antibiotics |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01100165A (en) * | 1987-10-13 | 1989-04-18 | Shionogi & Co Ltd | Oxime or hydroxylamine derivative based antimicrobial agent |
| EP0541086A1 (en) * | 1991-11-08 | 1993-05-12 | Kaken Pharmaceutical Co., Ltd. | Antibacterial 6-fluoro-quinolones having an oxime group on the substituent in position 7 |
-
1997
- 1997-04-04 US US08/825,992 patent/US5776944A/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01100165A (en) * | 1987-10-13 | 1989-04-18 | Shionogi & Co Ltd | Oxime or hydroxylamine derivative based antimicrobial agent |
| EP0541086A1 (en) * | 1991-11-08 | 1993-05-12 | Kaken Pharmaceutical Co., Ltd. | Antibacterial 6-fluoro-quinolones having an oxime group on the substituent in position 7 |
Non-Patent Citations (24)
| Title |
|---|
| Bouzard et al., "Fluoronaphthyridines as Antibacterial Agents. 4. Synthesis and Structure-Activity Relationships of 5-Substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acids", J. Med. Chem., vol. 35, pp. 518-525, 1992. |
| Bouzard et al., Fluoronaphthyridines as Antibacterial Agents. 4. Synthesis and Structure Activity Relationships of 5 Substituted 6 fluoro 7 (cycloalkylamino) 1,4 dihydro 4 oxo 1,8 naphthyridine 3 carboxylic Acids , J. Med. Chem., vol. 35, pp. 518 525, 1992. * |
| CA 114: 164195r, p. 775, 1991. * |
| CA119:203318h, p. 884, 1993. * |
| Cooper et al., "Preparation and in Vitro and in Vivo Evaluation of Quinolones with Selective Activity against Gram-Positive Organisms", J. Med. Chem., vol. 35, pp. 1392-1398, 1992. |
| Cooper et al., Preparation and in Vitro and in Vivo Evaluation of Quinolones with Selective Activity against Gram Positive Organisms , J. Med. Chem., vol. 35, pp. 1392 1398, 1992. * |
| Domagala et al., "1-Substituted, 7- 3- Ethylamoni) methyl!-1-pyrrolidinyl!-6,8-difluoror-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acids. New Quantititative Structure-Activity Relationships at N for the Quinolone Antibacterials", J. Med. Chem., vol. 31, pp. 991-1001,1988. |
| Domagala et al., "Synthesis and Biological Activity of 5-Amino-and 5-Hydroxyquinolones, and the Overwhelming Influence of the Remote N-Substituent in Determining the Structure-Activity Relationship", J. Med. Chem., vol. 34, pp. 1142-1154, 1991. |
| Domagala et al., 1 Substituted, 7 3 Ethylamoni) methyl 1 pyrrolidinyl 6,8 difluoror 1,4 dihydro 4 oxo 3 quinolinecarboxylic Acids. New Quantititative Structure Activity Relationships at N for the Quinolone Antibacterials , J. Med. Chem., vol. 31, pp. 991 1001,1988. * |
| Domagala et al., Synthesis and Biological Activity of 5 Amino and 5 Hydroxyquinolones, and the Overwhelming Influence of the Remote N Substituent in Determining the Structure Activity Relationship , J. Med. Chem., vol. 34, pp. 1142 1154, 1991. * |
| Koga et al., "Structure-Activity Relationships of Antibacterial 6,7- and 7,8-Disubstituted 1-Alkyl-1,4- dihydro-4-oixoquinoline-3-carboxylic Acids", J. Med. Chem., vol. 23, pp. 1358-1363, 1980. |
| Koga et al., Structure Activity Relationships of Antibacterial 6,7 and 7,8 Disubstituted 1 Alkyl 1,4 dihydro 4 oixoquinoline 3 carboxylic Acids , J. Med. Chem., vol. 23, pp. 1358 1363, 1980. * |
| Lesher et al., "I, 8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents", J. Med. Chem., vol. 5, pp. 1063-1065, 1962. |
| Lesher et al., I, 8 Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents , J. Med. Chem., vol. 5, pp. 1063 1065, 1962. * |
| Matsumoto et al., "AT-3295, a New Pyridonecarboxylic Acid Derivative with Potent Antibacterial Activity: Synthesis and Structure-activity Relationships", Proceedings of the 14th International Congress of Chemotheraphy pp. 1519-1520, 1985. |
| Matsumoto et al., AT 3295, a New Pyridonecarboxylic Acid Derivative with Potent Antibacterial Activity: Synthesis and Structure activity Relationships , Proceedings of the 14th International Congress of Chemotheraphy pp. 1519 1520, 1985. * |
| Parikh et al., "Sulfur trioxide in the Oxidation of Alcohols by Dimethyl Sulfoxide", JACS., vol. 89, pp. 5505-5507, 1967. |
| Parikh et al., Sulfur trioxide in the Oxidation of Alcohols by Dimethyl Sulfoxide , JACS., vol. 89, pp. 5505 5507, 1967. * |
| Rosen et al., "Design, Synthesis, and Properties of (4S)-7-(4-Amino-2-substituted-pyrrolidin-1-yl) quinolone-3-carboxylic Acids", J. Med. Chem., vol. 31, pp. 1598-1611, 1988. |
| Rosen et al., Design, Synthesis, and Properties of (4S) 7 (4 Amino 2 substituted pyrrolidin 1 yl) quinolone 3 carboxylic Acids , J. Med. Chem., vol. 31, pp. 1598 1611, 1988. * |
| Sato et al., "In Vitro and In Vivo Activity of DL-8280, a New Oxazine Derivative", J. Antimicrob. Agents Chemother, vol. 23, pp. 548-553, 1982. |
| Sato et al., In Vitro and In Vivo Activity of DL 8280, a New Oxazine Derivative , J. Antimicrob. Agents Chemother, vol. 23, pp. 548 553, 1982. * |
| Wise et al., "In Vitro Activity of Bay 09867, a New Quinoline Derivative, Compared with Those of Other Antimicrobial Agents", J. Antimicrob. Agents Chemother, vol. 23, pp. 559-564, 1983. |
| Wise et al., In Vitro Activity of Bay 09867, a New Quinoline Derivative, Compared with Those of Other Antimicrobial Agents , J. Antimicrob. Agents Chemother, vol. 23, pp. 559 564, 1983. * |
Cited By (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080039488A1 (en) * | 1997-03-21 | 2008-02-14 | Lg Life Sciences, Ltd. | Salt of naphthyridine carboxylic acid derivative |
| US20040198767A1 (en) * | 1997-03-21 | 2004-10-07 | Lg Life Sciences, Ltd. | Salt of naphthyridine carboxylic acid derivative |
| US6723734B2 (en) * | 1997-03-21 | 2004-04-20 | Lg Life Sciences, Ltd. | Salt of naphthyridine carboxylic acid derivative |
| US7700617B2 (en) | 1997-03-21 | 2010-04-20 | Lg Life Sciences, Ltd. | Salt of naphthyridine carboxylic acid derivative |
| US20100240694A1 (en) * | 1997-03-21 | 2010-09-23 | Lg Life Sciences, Ltd. | Salt of naphthyridine carboxylic acid derivative |
| US20090182006A1 (en) * | 1997-03-21 | 2009-07-16 | Lg Life Sciences, Ltd. | Salt of naphthyridine carboxylic acid derivative |
| US6818771B1 (en) | 1998-09-18 | 2004-11-16 | Lg Life Sciences Limited | Process for the production of a naphthyridine carboxylic acid derivative (methanesulfonate sesquihydrate) |
| AU751060B2 (en) * | 1998-09-18 | 2002-08-08 | Lg Life Sciences Limited | Process for the production of a naphthyridine carboxylic acid derivative (methanesulfonate sesquihydrate) |
| US7595328B2 (en) | 1999-06-29 | 2009-09-29 | Lg Life Sciences Limited | Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria |
| US20040180903A1 (en) * | 1999-06-29 | 2004-09-16 | Jacques Dubois | Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria |
| US6803376B1 (en) | 1999-06-29 | 2004-10-12 | Smithkline Beecham Corporation | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
| US6262071B1 (en) * | 1999-06-29 | 2001-07-17 | Smithkline Beecham Corporation | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
| US20040229881A1 (en) * | 1999-06-29 | 2004-11-18 | Smithkline Beecham Corporation | Methods of use of antimicrobial compounds against pathogenic mycoplasma bacteria |
| US20050288300A1 (en) * | 1999-06-29 | 2005-12-29 | Lg Life Sciences Limited. | Methods of use fluoroquinolone compounds against maxillary sinus pathogenic bacteria |
| US6455540B1 (en) | 1999-06-29 | 2002-09-24 | Smithkline Beecham Corporation | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
| US20040097520A1 (en) * | 1999-07-08 | 2004-05-20 | Smithkline Beecham Corporation | Methods of use of fluoroquinolone compounds against ciprofloxacin-resistant and ciprofloxacin-sensitive pathogenic bacteria |
| US20040138292A1 (en) * | 1999-09-03 | 2004-07-15 | SB Pharmco Puerto Rico Inc of the United States Corporation Company. | Intermediates for the production of quinolone carboxylic acid derivatives |
| US20050033064A1 (en) * | 1999-09-03 | 2005-02-10 | Lg Life Sciences Limited | Intermediates for the production of quinolone carboxylic acid derivatives |
| US6803467B2 (en) | 1999-09-03 | 2004-10-12 | Lg Life Sciences Limited | Intermediates for the production of quinolone carboxylic acid derivatives |
| US7232907B2 (en) | 1999-09-03 | 2007-06-19 | Lg Life Sciences Limited | Process for production of naphthyridine-3-carboxylic acid derivatives |
| US20050176961A1 (en) * | 1999-09-03 | 2005-08-11 | Sb Pharmco Puerto Rico Inc. | Process for production of naphthyridine-3-carboxylic acid derivatives |
| US6703512B1 (en) | 1999-09-03 | 2004-03-09 | Sb Pharmco Puerto Rico Inc. Of The United States Corporation Company | Intermediates for the production of quinolone carboxylic acid derivatives |
| US20050032813A1 (en) * | 1999-09-14 | 2005-02-10 | Jacques Dubois | Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria |
| US6919351B2 (en) | 2000-10-12 | 2005-07-19 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors |
| US20040034221A1 (en) * | 2000-10-12 | 2004-02-19 | Anthony Neville J | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| USRE45090E1 (en) | 2001-05-15 | 2014-08-26 | Panduit Corp. | Cable tie with wide neck |
| US20050043546A1 (en) * | 2001-08-02 | 2005-02-24 | Brechtelsbauer Clemens Michael Helmut | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof |
| US7199242B2 (en) * | 2001-08-02 | 2007-04-03 | Lg Life Sciences Limited | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof |
| US20050176955A1 (en) * | 2002-03-15 | 2005-08-11 | Melissa Egbertson | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors |
| US7323460B2 (en) | 2002-03-15 | 2008-01-29 | Merck & Co., Inc. | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors |
| US7361762B2 (en) | 2002-04-08 | 2008-04-22 | Lg Life Sciences Ltd. | Process for preparing acid salts of Gemifloxacin |
| US20050148622A1 (en) * | 2002-04-08 | 2005-07-07 | Lg Life Sciences Ltd | Process for preparing acid salts of gemifloxacin |
| US7687629B2 (en) * | 2003-03-07 | 2010-03-30 | Lg Life Sciences Ltd. | Process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate |
| US20070282107A1 (en) * | 2003-03-07 | 2007-12-06 | Lg Life Sciences Ltd. | New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate |
| US20060059919A1 (en) * | 2004-09-07 | 2006-03-23 | Leachman David P | System and method for improving thermal efficiency of dry low emissions combustor assemblies |
| EP2969004A1 (en) | 2013-03-15 | 2016-01-20 | Melinta Therapeutics, Inc. | Methods of treating infections in overweight and obese patients using antibiotics |
| US12036219B2 (en) | 2013-03-15 | 2024-07-16 | Melinta Subsidiary Corp. | Methods of treating infections in overweight and obese patients using antibiotics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5869670A (en) | 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof | |
| US5776944A (en) | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof | |
| US5436254A (en) | Carbostyril derivatives | |
| US6602882B1 (en) | Quinoline derivatives and their use as antibacterial agents | |
| US5304556A (en) | Benza-triazinone derivatives | |
| US5629430A (en) | Trifluoromethylpyrroloindolecarboxylic acid ester and process for production thereof | |
| US20060183762A1 (en) | 3-aminoquinazolin-2,4-dione antibacterial agents | |
| US9598407B2 (en) | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | |
| EP0224919B1 (en) | new thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | |
| EP2742044B1 (en) | Antibacterial homopiperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones | |
| US5412098A (en) | Quinolone derivative or salt thereof and antibacterial containing the same | |
| US5399553A (en) | Tricyclic compound or salts thereof, method for producing the same and anti-microbial agent containing the same | |
| JPS647996B2 (en) | ||
| US5252734A (en) | Antibacterial 5-alkylquinolonecarboxylic acids | |
| US5424433A (en) | Intermediates for 3-oxadiazoly-1,6-naphthyridine derivatives | |
| US4963566A (en) | Benzimidazolyl-sulfinyl-tetrahydroquinolines | |
| US5861412A (en) | Dihydro-isoquinoline compounds and their use as pharmaceuticals | |
| RU2120940C1 (en) | Derivatives of quinoline- or naphthyridine carboxylic acid and methods of their synthesis | |
| EP0311948A2 (en) | Quinolonecarboxylic acid compounds and pharmaceutical use thereof | |
| US6492373B2 (en) | 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions | |
| US5643919A (en) | Anellated dihydropyridines and the use thereof for the production of pharmaceutical preparation | |
| JPH02229165A (en) | Carbostyril derivative | |
| JP2008540504A (en) | 4 "amino-linked macrolides useful for the treatment of bacterial infections | |
| KR100222083B1 (en) | Novel quinoline carboxylic acid derivatives having (3-aminomethyl-4-benzyloxime)pyrrolidine substituient at 7 position and process for preparation thereof | |
| JPH0625224A (en) | New pyridonecarboxylic acid azitidine derivative having antimicrobial activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: LG CHEMICAL LTD., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HONG, CHANG YONG;KIM, YOUNG KWAN;KIM, SE HO;AND OTHERS;REEL/FRAME:008694/0657 Effective date: 19970509 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| AS | Assignment |
Owner name: LG CHEM INVESTMENT LTD., KOREA, REPUBLIC OF Free format text: CHANGE OF NAME;ASSIGNOR:LG CHEMICAL LTD.;REEL/FRAME:013570/0817 Effective date: 20010403 |
|
| AS | Assignment |
Owner name: LG CHEM INVESTMENT LTD., KOREA, REPUBLIC OF Free format text: CHANGE OF NAME;ASSIGNOR:LG CHEMICAL LTD.;REEL/FRAME:013563/0644 Effective date: 20010403 Owner name: LG LIFE SCIENCES, LTD., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LG CHEM INVESTMENT, LTD.;REEL/FRAME:013570/0131 Effective date: 20021129 Owner name: LG LIFE SCIENCES, LTD., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LG CHEM INVESTMENT, LTD.;REEL/FRAME:013570/0624 Effective date: 20021129 |
|
| RR | Request for reexamination filed |
Effective date: 20021227 |
|
| PTEF | Application for a patent term extension |
Free format text: PRODUCT NAME: FACTIVE (GEMIFLOXACIN MESYLATE); REQUESTED FOR 659 DAYS Filing date: 20030529 Expiry date: 20150615 |
|
| B1 | Reexamination certificate first reexamination |
Free format text: CLAIMS 1-11, 15 AND 16 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 12, 13 AND 14, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE. NEW CLAIMS 17-33 AND 34 ARE ADDED AND DETERMINED TO BE PATENTABLE. |
|
| B1 | Reexamination certificate first reexamination |
Free format text: CLAIMS 1-11, 15 AND 16 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 12, 13 AND 14, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE. NEW CLAIMS 17-33 AND 34 ARE ADDED AND DETERMINED TO BE PATENTABLE. |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| PTEG | Grant of a patent term extension |
Free format text: PRODUCT NAME: FACTIVE (GEMIFLOXACIN MESYLATE) Filing date: 20030529 Expiry date: 20150615 Extension date: 20170404 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 12 |